<?xml version="1.0" encoding="utf-8"?>
<Label drug="SAMSCA" setid="5526617c-c7b9-4556-886d-729bbabbc566">
<Text><Section name="Boxed Warning section" id="34066-1">
WARNING: INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM 

 SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. 

 Too rapid correction of hyponatremia (e.g., &gt;12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable. 

 WARNING: INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM 

 See full prescribing information for complete boxed warning. 

 • 
 SAMSCA should be initiated and re-initiated in patients only in a hospital where serum sodium can be monitored closely. 

 • 
 Too rapid correction of hyponatremia (e.g., &gt;12 mEq/L/24 hours) can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable.</Section>
<Section name="DOSAGE &amp; ADMINISTRATION SECTION" id="34068-7">
2 DOSAGE AND ADMINISTRATION 

 • SAMSCA should be initiated and re-initiated in a hospital ( 2.1 ) 

 • The recommended starting dose is 15 mg once daily. Dosage may be increased at intervals ≥24 hr to 30 mg once daily, and to a maximum of 60 mg once daily as needed to raise serum sodium. ( 2.1 ) 

 2.1 Usual Dosage in Adults 

 Patients should be in a hospital for initiation and re-initiation of therapy to evaluate the therapeutic response and because too rapid correction of hyponatremia can cause osmotic demyelination resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma and death. 
 The usual starting dose for SAMSCA is 15 mg administered once daily without regard to meals. Increase the dose to 30 mg once daily, after at least 24 hours, to a maximum of 60 mg once daily, as needed to achieve the desired level of serum sodium. Do not administer SAMSCA for more than 30 days to minimize the risk of liver injury [see Warnings and Precautions (5.2) ]. 

 During initiation and titration, frequently monitor for changes in serum electrolytes and volume. Avoid fluid restriction during the first 24 hours of therapy. Patients receiving SAMSCA should be advised that they can continue ingestion of fluid in response to thirst [see Warnings and Precautions (5.1) ]. 

 2.2 Drug Withdrawal 

 Following discontinuation from SAMSCA, patients should be advised to resume fluid restriction and should be monitored for changes in serum sodium and volume status. 

 2.3 Co-Administration with CYP 3A Inhibitors, CYP 3A Inducers and P-gp Inhibitors 

 CYP 3A Inhibitors 

 Tolvaptan is metabolized by CYP 3A, and use with strong CYP 3A inhibitors causes a marked (5-fold) increase in exposure [see Contraindications (4.4) ] . The effect of moderate CYP 3A inhibitors on tolvaptan exposure has not been assessed. Avoid co-administration of SAMSCA and moderate CYP 3A inhibitors [see Warnings and Precautions (5.5) , Drug Interactions (7.1) ]. 

 CYP 3A Inducers 

 Co-administration of SAMSCA with potent CYP 3A inducers (e.g., rifampin) reduces tolvaptan plasma concentrations by 85%. Therefore, the expected clinical effects of SAMSCA may not be observed at the recommended dose. Patient response should be monitored and the dose adjusted accordingly [see Warnings and Precautions (5.5) , Drug Interactions (7.1) ]. 

 P-gp Inhibitors 

 Tolvaptan is a substrate of P-gp. Co-administration of SAMSCA with inhibitors of P-gp (e.g., cyclosporine) may necessitate a decrease in SAMSCA dose [see Warnings and Precautions (5.5) , Drug Interactions (7.1) ].</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
4 CONTRAINDICATIONS 

 SAMSCA is contraindicated in the following conditions: 

 • Need to raise serum sodium acutely ( 4.1 ) 

 • Patients who are unable to respond appropriately to thirst ( 4.2 ) 

 • Hypovolemic hyponatremia ( 4.3 ) 

 • Concomitant use of strong CYP 3A inhibitors ( 4.4 ) 

 • Anuria ( 4.5 ) 

 • Hypersensitivity ( 4.6 ) 

 4.1 Urgent Need to Raise Serum Sodium Acutely 

 SAMSCA has not been studied in a setting of urgent need to raise serum sodium acutely. 

 4.2 Inability of the Patient to Sense or Appropriately Respond to Thirst 

 Patients who are unable to auto-regulate fluid balance are at substantially increased risk of incurring an overly rapid correction of serum sodium, hypernatremia and hypovolemia. 

 4.3 Hypovolemic Hyponatremia 

 Risks associated with worsening hypovolemia, including complications such as hypotension and renal failure, outweigh possible benefits. 

 4.4 Concomitant Use of Strong CYP 3A Inhibitors 

 Ketoconazole 200 mg administered with tolvaptan increased tolvaptan exposure by 5-fold. Larger doses would be expected to produce larger increases in tolvaptan exposure. There is not adequate experience to define the dose adjustment that would be needed to allow safe use of tolvaptan with strong CYP 3A inhibitors such as clarithromycin, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, and telithromycin. 

 4.5 Anuric Patients 

 In patients unable to make urine, no clinical benefit can be expected. 

 4.6 Hypersensitivity 

 SAMSCA is contraindicated in patients with hypersensitivity (e.g. anaphylactic shock, rash generalized) to tolvaptan or any component of the product [see Adverse Reactions (6.2) ].</Section>
<Section name="WARNINGS AND PRECAUTIONS SECTION" id="43685-7">
5 WARNINGS AND PRECAUTIONS 

 • Liver injury: Limit treatment duration to 30 days. If hepatic injury is suspected, discontinue SAMSCA. Avoid use in patients with underlying liver disease ( 5.2 ) 

 • Dehydration and hypovolemia may require intervention ( 5.3 ) 

 • Avoid use with hypertonic saline ( 5.4 ) 

 • Avoid use with CYP 3A inducers and moderate CYP 3A inhibitors ( 5.5 ) 

 • Consider dose reduction if co-administered with P-gp inhibitors ( 5.5 ) 

 • Monitor serum potassium in patients with potassium &gt;5 mEq/L or on drugs known to increase potassium ( 5.6 ) 

 5.1 Too Rapid Correction of Serum Sodium Can Cause Serious Neurologic Sequelae (see BOXED WARNING) 

 Osmotic demyelination syndrome is a risk associated with too rapid correction of hyponatremia (e.g., &gt;12 mEq/L/24 hours). Osmotic demyelination results in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma or death. In susceptible patients, including those with severe malnutrition, alcoholism or advanced liver disease, slower rates of correction may be advisable. In controlled clinical trials in which tolvaptan was administered in titrated doses starting at 15 mg once daily, 7% of tolvaptan-treated subjects with a serum sodium &lt;130 mEq/L had an increase in serum sodium greater than 8 mEq/L at approximately 8 hours and 2% had an increase greater than 12 mEq/L at 24 hours. Approximately 1% of placebo-treated subjects with a serum sodium &lt;130 mEq/L had a rise greater than 8 mEq/L at 8 hours and no patient had a rise greater than 12 mEq/L/24 hours. Osmotic demyelination syndrome has been reported in association with SAMSCA therapy [see Adverse Reactions (6.2) ]. Patients treated with SAMSCA should be monitored to assess serum sodium concentrations and neurologic status, especially during initiation and after titration. Subjects with SIADH or very low baseline serum sodium concentrations may be at greater risk for too-rapid correction of serum sodium. In patients receiving SAMSCA who develop too rapid a rise in serum sodium, discontinue or interrupt treatment with SAMSCA and consider administration of hypotonic fluid. Fluid restriction during the first 24 hours of therapy with SAMSCA may increase the likelihood of overly-rapid correction of serum sodium, and should generally be avoided. Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. 

 5.2 Liver Injury 

 SAMSCA can cause serious and potentially fatal liver injury. In a placebo-controlled and open label extension study of chronically administered tolvaptan in patients with autosomal dominant polycystic kidney disease, cases of serious liver injury attributed to tolvaptan were observed. An increased incidence of ALT greater than three times the upper limit of normal was associated with tolvaptan (42/958 or 4.4%) compared to placebo (5/484 or 1.0%). Cases of serious liver injury were generally observed starting 3 months after initiation of tolvaptan although elevations of ALT occurred prior to 3 months. 
 Patients with symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice should discontinue treatment with SAMSCA. 
 Limit duration of therapy with SAMSCA to 30 days. Avoid use in patients with underlying liver disease, including cirrhosis, because the ability to recover from liver injury may be impaired [see Adverse Reactions (6.1) ] . 

 5.3 Dehydration and Hypovolemia 

 SAMSCA therapy induces copious aquaresis, which is normally partially offset by fluid intake. Dehydration and hypovolemia can occur, especially in potentially volume-depleted patients receiving diuretics or those who are fluid restricted. In multiple-dose, placebo-controlled trials in which 607 hyponatremic patients were treated with tolvaptan, the incidence of dehydration was 3.3% for tolvaptan and 1.5% for placebo-treated patients. In patients receiving SAMSCA who develop medically significant signs or symptoms of hypovolemia, interrupt or discontinue SAMSCA therapy and provide supportive care with careful management of vital signs, fluid balance and electrolytes. Fluid restriction during therapy with SAMSCA may increase the risk of dehydration and hypovolemia. Patients receiving SAMSCA should continue ingestion of fluid in response to thirst. 

 5.4 Co-administration with Hypertonic Saline 

 Concomitant use with hypertonic saline is not recommended. 

 5.5 Drug Interactions 

 Other Drugs Affecting Exposure to Tolvaptan 

 CYP 3A Inhibitors 
 Tolvaptan is a substrate of CYP 3A. CYP 3A inhibitors can lead to a marked increase in tolvaptan concentrations [see Dosage and Administration (2.3) , Drug Interactions (7.1) ]. Do not use SAMSCA with strong inhibitors of CYP 3A [see Contraindications (4.4) ] and avoid concomitant use with moderate CYP 3A inhibitors. 

 CYP 3A Inducers 
 Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment. If co-administered with CYP 3A inducers, the dose of SAMSCA may need to be increased [see Dosage and Administration (2.3) , Drug Interactions (7.1) ]. 

 P-gp Inhibitors 
 The dose of SAMSCA may have to be reduced when SAMSCA is co-administered with P-gp inhibitors, e.g., cyclosporine [see Dosage and Administration (2.3) , Drug Interactions (7.1) ]. 

 5.6 Hyperkalemia or Drugs that Increase Serum Potassium 

 Treatment with tolvaptan is associated with an acute reduction of the extracellular fluid volume which could result in increased serum potassium. Serum potassium levels should be monitored after initiation of tolvaptan treatment in patients with a serum potassium &gt;5 mEq/L as well as those who are receiving drugs known to increase serum potassium levels.</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
7 DRUG INTERACTIONS 

 7.1 Effects of Drugs on Tolvaptan 

 Ketoconazole and Other Strong CYP 3A Inhibitors 

 SAMSCA is metabolized primarily by CYP 3A. Ketoconazole is a strong inhibitor of CYP 3A and also an inhibitor of P-gp. Co-administration of SAMSCA and ketoconazole 200 mg daily results in a 5-fold increase in exposure to tolvaptan. Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure. Thus, SAMSCA and strong CYP 3A inhibitors should not be co-administered [see Dosage and Administration (2.3) and Contraindications (4.4) ]. 

 Moderate CYP 3A Inhibitors 

 The impact of moderate CYP 3A inhibitors (e.g., erythromycin, fluconazole, aprepitant, diltiazem and verapamil) on the exposure to co-administered tolvaptan has not been assessed. A substantial increase in the exposure to tolvaptan would be expected when SAMSCA is co-administered with moderate CYP 3A inhibitors. Co-administration of SAMSCA with moderate CYP3A inhibitors should therefore generally be avoided [see Dosage and Administration (2.3) and Warnings and Precautions (5.5) ]. 

 Grapefruit Juice 

 Co-administration of grapefruit juice and SAMSCA results in a 1.8-fold increase in exposure to tolvaptan [see Dose and Administration (2.3) and Warnings and Precautions (5.5) ]. 

 P-gp Inhibitors 

 Reduction in the dose of SAMSCA may be required in patients concomitantly treated with P-gp inhibitors, such as e.g., cyclosporine, based on clinical response [see Dose and Administration (2.3) and Warnings and Precautions (5.5) ]. 

 Rifampin and Other CYP 3A Inducers 

 Rifampin is an inducer of CYP 3A and P-gp. Co-administration of rifampin and SAMSCA reduces exposure to tolvaptan by 85%. Therefore, the expected clinical effects of SAMSCA in the presence of rifampin and other inducers (e.g., rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine and St. John's Wort) may not be observed at the usual dose levels of SAMSCA. The dose of SAMSCA may have to be increased [ Dosage and Administration (2.3) and Warnings and Precautions (5.5) ] . 

 Lovastatin, Digoxin, Furosemide, and Hydrochlorothiazide 

 Co-administration of lovastatin, digoxin, furosemide, and hydrochlorothiazide with SAMSCA has no clinically relevant impact on the exposure to tolvaptan. 

 7.2 Effects of Tolvaptan on Other Drugs 

 Digoxin 

 Digoxin is a P-gp substrate. Co-administration of SAMSCA with digoxin increased digoxin AUC by 20% and Cmax by 30%. 

 Warfarin, Amiodarone, Furosemide, and Hydrochlorothiazide 

 Co-administration of tolvaptan does not appear to alter the pharmacokinetics of warfarin, furosemide, hydrochlorothiazide, or amiodarone (or its active metabolite, desethylamiodarone) to a clinically significant degree. 

 Lovastatin 

 SAMSCA is a weak inhibitor of CYP 3A. Co-administration of lovastatin and SAMSCA increases the exposure to lovastatin and its active metabolite lovastatin-β hydroxyacid by factors of 1.4 and 1.3, respectively. This is not a clinically relevant change. 

 Pharmacodynamic Interactions 

 Tolvaptan produces a greater 24 hour urine volume/excretion rate than does furosemide or hydrochlorothiazide. Concomitant administration of tolvaptan with furosemide or hydrochlorothiazide results in a 24 hour urine volume/excretion rate that is similar to the rate after tolvaptan administration alone. 
 Although specific interaction studies were not performed, in clinical studies tolvaptan was used concomitantly with beta-blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics. Adverse reactions of hyperkalemia were approximately 1-2% higher when tolvaptan was administered with angiotensin receptor blockers, angiotensin converting enzyme inhibitors and potassium sparing diuretics compared to administration of these medications with placebo. Serum potassium levels should be monitored during concomitant drug therapy. 
 As a V 2 -receptor antagonist, tolvaptan may interfere with the V 2 -agonist activity of desmopressin (dDAVP). In a male subject with mild Von Willebrand (vW) disease, intravenous infusion of dDAVP 2 hours after administration of oral tolvaptan did not produce the expected increases in vW Factor Antigen or Factor VIII activity. It is not recommended to administer SAMSCA with a V 2 -agonist.</Section>
</Text><Sentences>
<Sentence id="157" LabelDrug="SAMSCA" section="34068-7">
<SentenceText>Co-administration of SAMSCA with inhibitors of P-gp ( e.g. , cyclosporine ) may necessitate a decrease in SAMSCA dose see Warnings and Precautions ( 5.5 ) , Drug Interactions ( 7.1 ) .</SentenceText>
<Mention id="M3" type="Trigger" span="76 15;94 8;113 4" str="may necessitate | decrease | dose"/>
<Mention id="M2" type="Precipitant" span="61 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M4" type="Precipitant" span="33 18" str="inhibitors of P-gp" code="n0000185503"/>
<Interaction id="I1" type="Unspecified interaction" trigger="M3" precipitant="M2"/>
<Interaction id="I2" type="Unspecified interaction" trigger="M3" precipitant="M4"/>
</Sentence>
<Sentence id="157" LabelDrug="SAMSCA" section="34068-7">
<SentenceText>Co-administration of SAMSCA with inhibitors of P-gp ( e.g. , cyclosporine ) may necessitate a decrease in SAMSCA dose see Warnings and Precautions ( 5.5 ) , Drug Interactions ( 7.1 ) .</SentenceText>
<Mention id="M7" type="Trigger" span="76 15;94 8;113 4" str="may necessitate | decrease | dose"/>
<Mention id="M6" type="Precipitant" span="61 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M8" type="Precipitant" span="33 18" str="inhibitors of P-gp" code="n0000185503"/>
<Interaction id="I3" type="Unspecified interaction" trigger="M7" precipitant="M6"/>
<Interaction id="I4" type="Unspecified interaction" trigger="M7" precipitant="M8"/>
</Sentence>
<Sentence id="158" LabelDrug="SAMSCA" section="34068-7">
<SentenceText>Co-administration of SAMSCA with potent CYP 3A inducers ( e.g. , rifampin ) reduces tolvaptan plasma concentrations by 85 % .</SentenceText>
<Mention id="M11" type="Trigger" span="76 7;94 21" str="reduces | plasma concentrations"/>
<Mention id="M10" type="Precipitant" span="33 22" str="potent CYP 3A inducers" code="n0000190118"/>
<Mention id="M12" type="Precipitant" span="65 8" str="rifampin" code="N0000006026"/>
<Interaction id="I5" type="Pharmacokinetic interaction" trigger="M11" precipitant="M10" effect="C54356"/>
<Interaction id="I6" type="Pharmacokinetic interaction" trigger="M11" precipitant="M12" effect="C54356"/>
</Sentence>
<Sentence id="158" LabelDrug="SAMSCA" section="34068-7">
<SentenceText>Co-administration of SAMSCA with potent CYP 3A inducers ( e.g. , rifampin ) reduces tolvaptan plasma concentrations by 85 % .</SentenceText>
<Mention id="M15" type="Trigger" span="76 7;94 21" str="reduces | plasma concentrations"/>
<Mention id="M14" type="Precipitant" span="33 22" str="potent CYP 3A inducers" code="n0000190118"/>
<Mention id="M16" type="Precipitant" span="65 8" str="rifampin" code="N0000006026"/>
<Interaction id="I7" type="Pharmacokinetic interaction" trigger="M15" precipitant="M14" effect="C54356"/>
<Interaction id="I8" type="Pharmacokinetic interaction" trigger="M15" precipitant="M16" effect="C54356"/>
</Sentence>
<Sentence id="159" LabelDrug="SAMSCA" section="34070-3">
<SentenceText>Ketoconazole 200 mg administered with tolvaptan increased tolvaptan exposure by 5-fold .</SentenceText>
<Mention id="M17" type="Trigger" span="48 9;68 8" str="increased | exposure"/>
<Mention id="M18" type="Precipitant" span="0 12" str="Ketoconazole" code="N0000007319"/>
<Interaction id="I9" type="Pharmacokinetic interaction" trigger="M17" precipitant="M18" effect="C54355"/>
</Sentence>
<Sentence id="160" LabelDrug="SAMSCA" section="34070-3">
<SentenceText>There is not adequate experience to define the dose adjustment that would be needed to allow safe use of tolvaptan with strong CYP 3A inhibitors such as clarithromycin , ketoconazole , itraconazole , ritonavir , indinavir , nelfinavir , saquinavir , nefazodone , and telithromycin .</SentenceText>
</Sentence>
<Sentence id="161" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>A substantial increase in the exposure to tolvaptan would be expected when SAMSCA is co-administered with moderate CYP 3A inhibitors.</SentenceText>
<Mention id="M19" type="Trigger" span="14 8;30 8" str="increase | exposure"/>
<Mention id="M20" type="Precipitant" span="106 26" str="moderate CYP 3A inhibitors" code="n0000191001"/>
<Interaction id="I10" type="Pharmacokinetic interaction" trigger="M19" precipitant="M20" effect="C54355"/>
</Sentence>
<Sentence id="162" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Adverse reactions of hyperkalemia were approximately 1-2 % higher when tolvaptan was administered with angiotensin receptor blockers , angiotensin converting enzyme inhibitors and potassium sparing diuretics compared to administration of these medications with placebo .</SentenceText>
<Mention id="M27" type="Trigger" span="0 17;59 6" str="Adverse reactions | higher"/>
<Mention id="M22" type="Precipitant" span="135 40" str="angiotensin converting enzyme inhibitors" code="N0000029130"/>
<Mention id="M29" type="SpecificInteraction" span="21 12" str="hyperkalemia" code="14140009: Hyperkalemia (disorder)"/>
<Mention id="M25" type="Precipitant" span="103 29" str="angiotensin receptor blockers" code="N0000000070"/>
<Mention id="M28" type="Precipitant" span="180 27" str="potassium sparing diuretics" code="N0000175418"/>
<Interaction id="I11" type="Pharmacodynamic interaction" trigger="M27" precipitant="M22" effect="M29"/>
<Interaction id="I12" type="Pharmacodynamic interaction" trigger="M27" precipitant="M25" effect="M29"/>
<Interaction id="I13" type="Pharmacodynamic interaction" trigger="M27" precipitant="M28" effect="M29"/>
</Sentence>
<Sentence id="162" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Adverse reactions of hyperkalemia were approximately 1-2 % higher when tolvaptan was administered with angiotensin receptor blockers , angiotensin converting enzyme inhibitors and potassium sparing diuretics compared to administration of these medications with placebo .</SentenceText>
<Mention id="M36" type="Trigger" span="0 17;59 6" str="Adverse reactions | higher"/>
<Mention id="M31" type="Precipitant" span="135 40" str="angiotensin converting enzyme inhibitors" code="N0000029130"/>
<Mention id="M38" type="SpecificInteraction" span="21 12" str="hyperkalemia" code="14140009: Hyperkalemia (disorder)"/>
<Mention id="M34" type="Precipitant" span="103 29" str="angiotensin receptor blockers" code="N0000000070"/>
<Mention id="M37" type="Precipitant" span="180 27" str="potassium sparing diuretics" code="N0000175418"/>
<Interaction id="I14" type="Pharmacodynamic interaction" trigger="M36" precipitant="M31" effect="M38"/>
<Interaction id="I15" type="Pharmacodynamic interaction" trigger="M36" precipitant="M34" effect="M38"/>
<Interaction id="I16" type="Pharmacodynamic interaction" trigger="M36" precipitant="M37" effect="M38"/>
</Sentence>
<Sentence id="162" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Adverse reactions of hyperkalemia were approximately 1-2 % higher when tolvaptan was administered with angiotensin receptor blockers , angiotensin converting enzyme inhibitors and potassium sparing diuretics compared to administration of these medications with placebo .</SentenceText>
<Mention id="M45" type="Trigger" span="0 17;59 6" str="Adverse reactions | higher"/>
<Mention id="M40" type="Precipitant" span="135 40" str="angiotensin converting enzyme inhibitors" code="N0000029130"/>
<Mention id="M47" type="SpecificInteraction" span="21 12" str="hyperkalemia" code="14140009: Hyperkalemia (disorder)"/>
<Mention id="M43" type="Precipitant" span="103 29" str="angiotensin receptor blockers" code="N0000000070"/>
<Mention id="M46" type="Precipitant" span="180 27" str="potassium sparing diuretics" code="N0000175418"/>
<Interaction id="I17" type="Pharmacodynamic interaction" trigger="M45" precipitant="M40" effect="M47"/>
<Interaction id="I18" type="Pharmacodynamic interaction" trigger="M45" precipitant="M43" effect="M47"/>
<Interaction id="I19" type="Pharmacodynamic interaction" trigger="M45" precipitant="M46" effect="M47"/>
</Sentence>
<Sentence id="163" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Although specific interaction studies were not performed , in clinical studies tolvaptan was used concomitantly with beta-blockers , angiotensin receptor blockers , angiotensin converting enzyme inhibitors and potassium sparing diuretics .</SentenceText>
</Sentence>
<Sentence id="164" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>As a V2-receptor antagonist , tolvaptan may interfere with the V2-agonist activity of desmopressin ( dDAVP ) .</SentenceText>
<Mention id="M48" type="Trigger" span="44 9" str="interfere"/>
<Mention id="M49" type="Precipitant" span="86 12" str="desmopressin" code="N0000147801"/>
<Mention id="M50" type="SpecificInteraction" span="44 9;63 35" str="interfere | V2-agonist activity of desmopressin" code="NO MAP"/>
<Interaction id="I20" type="Pharmacodynamic interaction" trigger="M48" precipitant="M49" effect="M50"/>
</Sentence>
<Sentence id="165" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of lovastatin , digoxin , furosemide , and hydrochlorothiazide with SAMSCA has no clinically relevant impact on the exposure to tolvaptan .</SentenceText>
</Sentence>
<Sentence id="166" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of lovastatin and SAMSCA increases the exposure to lovastatin and its active metabolite lovastatin - hydroxyacid by factors of 1.4 and 1.3 , respectively .</SentenceText>
<Mention id="M51" type="Trigger" span="43 9;57 8" str="increases | exposure"/>
<Mention id="M52" type="Precipitant" span="21 10" str="lovastatin" code="N0000007106"/>
<Interaction id="I21" type="Pharmacokinetic interaction" trigger="M51" precipitant="M52" effect="C54357"/>
</Sentence>
<Sentence id="167" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of rifampin and SAMSCA reduces exposure to tolvaptan by 85 % .</SentenceText>
<Mention id="M53" type="Trigger" span="41 16" str="reduces exposure"/>
<Mention id="M54" type="Precipitant" span="21 8" str="rifampin" code="N0000006026"/>
<Interaction id="I22" type="Pharmacokinetic interaction" trigger="M53" precipitant="M54" effect="C54356"/>
</Sentence>
<Sentence id="168" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA and ketoconazole 200 mg daily results in a 5-fold increase in exposure to tolvaptan .</SentenceText>
<Mention id="M55" type="Trigger" span="58 10;78 8;90 8" str="results in | increase | exposure"/>
<Mention id="M56" type="Precipitant" span="32 12" str="ketoconazole" code="N0000007319"/>
<Interaction id="I23" type="Pharmacokinetic interaction" trigger="M55" precipitant="M56" effect="C54355"/>
</Sentence>
<Sentence id="169" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA and ketoconazole 200mg daily results in a 5-fold increase in exposure to tolvaptan.</SentenceText>
<Mention id="M57" type="Trigger" span="57 10;77 8;89 8" str="results in | increase | exposure"/>
<Mention id="M58" type="Precipitant" span="32 12" str="ketoconazole" code="N0000007319"/>
<Interaction id="I24" type="Pharmacokinetic interaction" trigger="M57" precipitant="M58" effect="C54355"/>
</Sentence>
<Sentence id="170" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .</SentenceText>
<Mention id="M75" type="Trigger" span="257 5;279 8;301 8" str="cause | increase | exposure"/>
<Mention id="M60" type="Precipitant" span="107 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M62" type="Precipitant" span="80 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M64" type="Precipitant" span="124 12" str="itraconazole" code="N0000006753"/>
<Mention id="M66" type="Precipitant" span="40 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M68" type="Precipitant" span="195 10" str="nefazodone" code="N0000007250"/>
<Mention id="M70" type="Precipitant" span="168 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M72" type="Precipitant" span="181 9" str="ritonavir" code="N0000007423"/>
<Mention id="M74" type="Precipitant" span="155 10" str="saquinavir" code="N0000007376"/>
<Mention id="M76" type="Precipitant" span="139 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I25" type="Pharmacokinetic interaction" trigger="M75" precipitant="M60" effect="C54355"/>
<Interaction id="I26" type="Pharmacokinetic interaction" trigger="M75" precipitant="M62" effect="C54355"/>
<Interaction id="I27" type="Pharmacokinetic interaction" trigger="M75" precipitant="M64" effect="C54355"/>
<Interaction id="I28" type="Pharmacokinetic interaction" trigger="M75" precipitant="M66" effect="C54355"/>
<Interaction id="I29" type="Pharmacokinetic interaction" trigger="M75" precipitant="M68" effect="C54355"/>
<Interaction id="I30" type="Pharmacokinetic interaction" trigger="M75" precipitant="M70" effect="C54355"/>
<Interaction id="I31" type="Pharmacokinetic interaction" trigger="M75" precipitant="M72" effect="C54355"/>
<Interaction id="I32" type="Pharmacokinetic interaction" trigger="M75" precipitant="M74" effect="C54355"/>
<Interaction id="I33" type="Pharmacokinetic interaction" trigger="M75" precipitant="M76" effect="C54355"/>
</Sentence>
<Sentence id="170" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .</SentenceText>
<Mention id="M93" type="Trigger" span="257 5;279 8;301 8" str="cause | increase | exposure"/>
<Mention id="M78" type="Precipitant" span="107 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M80" type="Precipitant" span="80 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M82" type="Precipitant" span="124 12" str="itraconazole" code="N0000006753"/>
<Mention id="M84" type="Precipitant" span="40 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M86" type="Precipitant" span="195 10" str="nefazodone" code="N0000007250"/>
<Mention id="M88" type="Precipitant" span="168 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M90" type="Precipitant" span="181 9" str="ritonavir" code="N0000007423"/>
<Mention id="M92" type="Precipitant" span="155 10" str="saquinavir" code="N0000007376"/>
<Mention id="M94" type="Precipitant" span="139 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I34" type="Pharmacokinetic interaction" trigger="M93" precipitant="M78" effect="C54355"/>
<Interaction id="I35" type="Pharmacokinetic interaction" trigger="M93" precipitant="M80" effect="C54355"/>
<Interaction id="I36" type="Pharmacokinetic interaction" trigger="M93" precipitant="M82" effect="C54355"/>
<Interaction id="I37" type="Pharmacokinetic interaction" trigger="M93" precipitant="M84" effect="C54355"/>
<Interaction id="I38" type="Pharmacokinetic interaction" trigger="M93" precipitant="M86" effect="C54355"/>
<Interaction id="I39" type="Pharmacokinetic interaction" trigger="M93" precipitant="M88" effect="C54355"/>
<Interaction id="I40" type="Pharmacokinetic interaction" trigger="M93" precipitant="M90" effect="C54355"/>
<Interaction id="I41" type="Pharmacokinetic interaction" trigger="M93" precipitant="M92" effect="C54355"/>
<Interaction id="I42" type="Pharmacokinetic interaction" trigger="M93" precipitant="M94" effect="C54355"/>
</Sentence>
<Sentence id="170" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .</SentenceText>
<Mention id="M111" type="Trigger" span="257 5;279 8;301 8" str="cause | increase | exposure"/>
<Mention id="M96" type="Precipitant" span="107 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M98" type="Precipitant" span="80 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M100" type="Precipitant" span="124 12" str="itraconazole" code="N0000006753"/>
<Mention id="M102" type="Precipitant" span="40 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M104" type="Precipitant" span="195 10" str="nefazodone" code="N0000007250"/>
<Mention id="M106" type="Precipitant" span="168 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M108" type="Precipitant" span="181 9" str="ritonavir" code="N0000007423"/>
<Mention id="M110" type="Precipitant" span="155 10" str="saquinavir" code="N0000007376"/>
<Mention id="M112" type="Precipitant" span="139 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I43" type="Pharmacokinetic interaction" trigger="M111" precipitant="M96" effect="C54355"/>
<Interaction id="I44" type="Pharmacokinetic interaction" trigger="M111" precipitant="M98" effect="C54355"/>
<Interaction id="I45" type="Pharmacokinetic interaction" trigger="M111" precipitant="M100" effect="C54355"/>
<Interaction id="I46" type="Pharmacokinetic interaction" trigger="M111" precipitant="M102" effect="C54355"/>
<Interaction id="I47" type="Pharmacokinetic interaction" trigger="M111" precipitant="M104" effect="C54355"/>
<Interaction id="I48" type="Pharmacokinetic interaction" trigger="M111" precipitant="M106" effect="C54355"/>
<Interaction id="I49" type="Pharmacokinetic interaction" trigger="M111" precipitant="M108" effect="C54355"/>
<Interaction id="I50" type="Pharmacokinetic interaction" trigger="M111" precipitant="M110" effect="C54355"/>
<Interaction id="I51" type="Pharmacokinetic interaction" trigger="M111" precipitant="M112" effect="C54355"/>
</Sentence>
<Sentence id="170" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .</SentenceText>
<Mention id="M129" type="Trigger" span="257 5;279 8;301 8" str="cause | increase | exposure"/>
<Mention id="M114" type="Precipitant" span="107 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M116" type="Precipitant" span="80 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M118" type="Precipitant" span="124 12" str="itraconazole" code="N0000006753"/>
<Mention id="M120" type="Precipitant" span="40 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M122" type="Precipitant" span="195 10" str="nefazodone" code="N0000007250"/>
<Mention id="M124" type="Precipitant" span="168 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M126" type="Precipitant" span="181 9" str="ritonavir" code="N0000007423"/>
<Mention id="M128" type="Precipitant" span="155 10" str="saquinavir" code="N0000007376"/>
<Mention id="M130" type="Precipitant" span="139 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I52" type="Pharmacokinetic interaction" trigger="M129" precipitant="M114" effect="C54355"/>
<Interaction id="I53" type="Pharmacokinetic interaction" trigger="M129" precipitant="M116" effect="C54355"/>
<Interaction id="I54" type="Pharmacokinetic interaction" trigger="M129" precipitant="M118" effect="C54355"/>
<Interaction id="I55" type="Pharmacokinetic interaction" trigger="M129" precipitant="M120" effect="C54355"/>
<Interaction id="I56" type="Pharmacokinetic interaction" trigger="M129" precipitant="M122" effect="C54355"/>
<Interaction id="I57" type="Pharmacokinetic interaction" trigger="M129" precipitant="M124" effect="C54355"/>
<Interaction id="I58" type="Pharmacokinetic interaction" trigger="M129" precipitant="M126" effect="C54355"/>
<Interaction id="I59" type="Pharmacokinetic interaction" trigger="M129" precipitant="M128" effect="C54355"/>
<Interaction id="I60" type="Pharmacokinetic interaction" trigger="M129" precipitant="M130" effect="C54355"/>
</Sentence>
<Sentence id="170" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .</SentenceText>
<Mention id="M147" type="Trigger" span="257 5;279 8;301 8" str="cause | increase | exposure"/>
<Mention id="M132" type="Precipitant" span="107 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M134" type="Precipitant" span="80 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M136" type="Precipitant" span="124 12" str="itraconazole" code="N0000006753"/>
<Mention id="M138" type="Precipitant" span="40 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M140" type="Precipitant" span="195 10" str="nefazodone" code="N0000007250"/>
<Mention id="M142" type="Precipitant" span="168 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M144" type="Precipitant" span="181 9" str="ritonavir" code="N0000007423"/>
<Mention id="M146" type="Precipitant" span="155 10" str="saquinavir" code="N0000007376"/>
<Mention id="M148" type="Precipitant" span="139 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I61" type="Pharmacokinetic interaction" trigger="M147" precipitant="M132" effect="C54355"/>
<Interaction id="I62" type="Pharmacokinetic interaction" trigger="M147" precipitant="M134" effect="C54355"/>
<Interaction id="I63" type="Pharmacokinetic interaction" trigger="M147" precipitant="M136" effect="C54355"/>
<Interaction id="I64" type="Pharmacokinetic interaction" trigger="M147" precipitant="M138" effect="C54355"/>
<Interaction id="I65" type="Pharmacokinetic interaction" trigger="M147" precipitant="M140" effect="C54355"/>
<Interaction id="I66" type="Pharmacokinetic interaction" trigger="M147" precipitant="M142" effect="C54355"/>
<Interaction id="I67" type="Pharmacokinetic interaction" trigger="M147" precipitant="M144" effect="C54355"/>
<Interaction id="I68" type="Pharmacokinetic interaction" trigger="M147" precipitant="M146" effect="C54355"/>
<Interaction id="I69" type="Pharmacokinetic interaction" trigger="M147" precipitant="M148" effect="C54355"/>
</Sentence>
<Sentence id="170" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .</SentenceText>
<Mention id="M165" type="Trigger" span="257 5;279 8;301 8" str="cause | increase | exposure"/>
<Mention id="M150" type="Precipitant" span="107 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M152" type="Precipitant" span="80 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M154" type="Precipitant" span="124 12" str="itraconazole" code="N0000006753"/>
<Mention id="M156" type="Precipitant" span="40 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M158" type="Precipitant" span="195 10" str="nefazodone" code="N0000007250"/>
<Mention id="M160" type="Precipitant" span="168 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M162" type="Precipitant" span="181 9" str="ritonavir" code="N0000007423"/>
<Mention id="M164" type="Precipitant" span="155 10" str="saquinavir" code="N0000007376"/>
<Mention id="M166" type="Precipitant" span="139 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I70" type="Pharmacokinetic interaction" trigger="M165" precipitant="M150" effect="C54355"/>
<Interaction id="I71" type="Pharmacokinetic interaction" trigger="M165" precipitant="M152" effect="C54355"/>
<Interaction id="I72" type="Pharmacokinetic interaction" trigger="M165" precipitant="M154" effect="C54355"/>
<Interaction id="I73" type="Pharmacokinetic interaction" trigger="M165" precipitant="M156" effect="C54355"/>
<Interaction id="I74" type="Pharmacokinetic interaction" trigger="M165" precipitant="M158" effect="C54355"/>
<Interaction id="I75" type="Pharmacokinetic interaction" trigger="M165" precipitant="M160" effect="C54355"/>
<Interaction id="I76" type="Pharmacokinetic interaction" trigger="M165" precipitant="M162" effect="C54355"/>
<Interaction id="I77" type="Pharmacokinetic interaction" trigger="M165" precipitant="M164" effect="C54355"/>
<Interaction id="I78" type="Pharmacokinetic interaction" trigger="M165" precipitant="M166" effect="C54355"/>
</Sentence>
<Sentence id="170" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .</SentenceText>
<Mention id="M183" type="Trigger" span="257 5;279 8;301 8" str="cause | increase | exposure"/>
<Mention id="M168" type="Precipitant" span="107 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M170" type="Precipitant" span="80 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M172" type="Precipitant" span="124 12" str="itraconazole" code="N0000006753"/>
<Mention id="M174" type="Precipitant" span="40 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M176" type="Precipitant" span="195 10" str="nefazodone" code="N0000007250"/>
<Mention id="M178" type="Precipitant" span="168 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M180" type="Precipitant" span="181 9" str="ritonavir" code="N0000007423"/>
<Mention id="M182" type="Precipitant" span="155 10" str="saquinavir" code="N0000007376"/>
<Mention id="M184" type="Precipitant" span="139 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I79" type="Pharmacokinetic interaction" trigger="M183" precipitant="M168" effect="C54355"/>
<Interaction id="I80" type="Pharmacokinetic interaction" trigger="M183" precipitant="M170" effect="C54355"/>
<Interaction id="I81" type="Pharmacokinetic interaction" trigger="M183" precipitant="M172" effect="C54355"/>
<Interaction id="I82" type="Pharmacokinetic interaction" trigger="M183" precipitant="M174" effect="C54355"/>
<Interaction id="I83" type="Pharmacokinetic interaction" trigger="M183" precipitant="M176" effect="C54355"/>
<Interaction id="I84" type="Pharmacokinetic interaction" trigger="M183" precipitant="M178" effect="C54355"/>
<Interaction id="I85" type="Pharmacokinetic interaction" trigger="M183" precipitant="M180" effect="C54355"/>
<Interaction id="I86" type="Pharmacokinetic interaction" trigger="M183" precipitant="M182" effect="C54355"/>
<Interaction id="I87" type="Pharmacokinetic interaction" trigger="M183" precipitant="M184" effect="C54355"/>
</Sentence>
<Sentence id="170" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .</SentenceText>
<Mention id="M201" type="Trigger" span="257 5;279 8;301 8" str="cause | increase | exposure"/>
<Mention id="M186" type="Precipitant" span="107 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M188" type="Precipitant" span="80 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M190" type="Precipitant" span="124 12" str="itraconazole" code="N0000006753"/>
<Mention id="M192" type="Precipitant" span="40 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M194" type="Precipitant" span="195 10" str="nefazodone" code="N0000007250"/>
<Mention id="M196" type="Precipitant" span="168 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M198" type="Precipitant" span="181 9" str="ritonavir" code="N0000007423"/>
<Mention id="M200" type="Precipitant" span="155 10" str="saquinavir" code="N0000007376"/>
<Mention id="M202" type="Precipitant" span="139 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I88" type="Pharmacokinetic interaction" trigger="M201" precipitant="M186" effect="C54355"/>
<Interaction id="I89" type="Pharmacokinetic interaction" trigger="M201" precipitant="M188" effect="C54355"/>
<Interaction id="I90" type="Pharmacokinetic interaction" trigger="M201" precipitant="M190" effect="C54355"/>
<Interaction id="I91" type="Pharmacokinetic interaction" trigger="M201" precipitant="M192" effect="C54355"/>
<Interaction id="I92" type="Pharmacokinetic interaction" trigger="M201" precipitant="M194" effect="C54355"/>
<Interaction id="I93" type="Pharmacokinetic interaction" trigger="M201" precipitant="M196" effect="C54355"/>
<Interaction id="I94" type="Pharmacokinetic interaction" trigger="M201" precipitant="M198" effect="C54355"/>
<Interaction id="I95" type="Pharmacokinetic interaction" trigger="M201" precipitant="M200" effect="C54355"/>
<Interaction id="I96" type="Pharmacokinetic interaction" trigger="M201" precipitant="M202" effect="C54355"/>
</Sentence>
<Sentence id="170" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .</SentenceText>
<Mention id="M219" type="Trigger" span="257 5;279 8;301 8" str="cause | increase | exposure"/>
<Mention id="M204" type="Precipitant" span="107 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M206" type="Precipitant" span="80 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M208" type="Precipitant" span="124 12" str="itraconazole" code="N0000006753"/>
<Mention id="M210" type="Precipitant" span="40 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M212" type="Precipitant" span="195 10" str="nefazodone" code="N0000007250"/>
<Mention id="M214" type="Precipitant" span="168 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M216" type="Precipitant" span="181 9" str="ritonavir" code="N0000007423"/>
<Mention id="M218" type="Precipitant" span="155 10" str="saquinavir" code="N0000007376"/>
<Mention id="M220" type="Precipitant" span="139 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I97" type="Pharmacokinetic interaction" trigger="M219" precipitant="M204" effect="C54355"/>
<Interaction id="I98" type="Pharmacokinetic interaction" trigger="M219" precipitant="M206" effect="C54355"/>
<Interaction id="I99" type="Pharmacokinetic interaction" trigger="M219" precipitant="M208" effect="C54355"/>
<Interaction id="I100" type="Pharmacokinetic interaction" trigger="M219" precipitant="M210" effect="C54355"/>
<Interaction id="I101" type="Pharmacokinetic interaction" trigger="M219" precipitant="M212" effect="C54355"/>
<Interaction id="I102" type="Pharmacokinetic interaction" trigger="M219" precipitant="M214" effect="C54355"/>
<Interaction id="I103" type="Pharmacokinetic interaction" trigger="M219" precipitant="M216" effect="C54355"/>
<Interaction id="I104" type="Pharmacokinetic interaction" trigger="M219" precipitant="M218" effect="C54355"/>
<Interaction id="I105" type="Pharmacokinetic interaction" trigger="M219" precipitant="M220" effect="C54355"/>
</Sentence>
<Sentence id="171" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.</SentenceText>
<Mention id="M237" type="Trigger" span="248 5;270 8;292 8" str="cause | increase | exposure"/>
<Mention id="M222" type="Precipitant" span="104 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M224" type="Precipitant" span="79 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M226" type="Precipitant" span="120 12" str="itraconazole" code="N0000006753"/>
<Mention id="M228" type="Precipitant" span="39 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M230" type="Precipitant" span="187 10" str="nefazodone" code="N0000007250"/>
<Mention id="M232" type="Precipitant" span="161 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M234" type="Precipitant" span="173 9" str="ritonavir" code="N0000007423"/>
<Mention id="M236" type="Precipitant" span="149 10" str="saquinavir" code="N0000007376"/>
<Mention id="M238" type="Precipitant" span="134 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I106" type="Pharmacokinetic interaction" trigger="M237" precipitant="M222" effect="C54355"/>
<Interaction id="I107" type="Pharmacokinetic interaction" trigger="M237" precipitant="M224" effect="C54355"/>
<Interaction id="I108" type="Pharmacokinetic interaction" trigger="M237" precipitant="M226" effect="C54355"/>
<Interaction id="I109" type="Pharmacokinetic interaction" trigger="M237" precipitant="M228" effect="C54355"/>
<Interaction id="I110" type="Pharmacokinetic interaction" trigger="M237" precipitant="M230" effect="C54355"/>
<Interaction id="I111" type="Pharmacokinetic interaction" trigger="M237" precipitant="M232" effect="C54355"/>
<Interaction id="I112" type="Pharmacokinetic interaction" trigger="M237" precipitant="M234" effect="C54355"/>
<Interaction id="I113" type="Pharmacokinetic interaction" trigger="M237" precipitant="M236" effect="C54355"/>
<Interaction id="I114" type="Pharmacokinetic interaction" trigger="M237" precipitant="M238" effect="C54355"/>
</Sentence>
<Sentence id="171" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.</SentenceText>
<Mention id="M255" type="Trigger" span="248 5;270 8;292 8" str="cause | increase | exposure"/>
<Mention id="M240" type="Precipitant" span="104 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M242" type="Precipitant" span="79 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M244" type="Precipitant" span="120 12" str="itraconazole" code="N0000006753"/>
<Mention id="M246" type="Precipitant" span="39 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M248" type="Precipitant" span="187 10" str="nefazodone" code="N0000007250"/>
<Mention id="M250" type="Precipitant" span="161 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M252" type="Precipitant" span="173 9" str="ritonavir" code="N0000007423"/>
<Mention id="M254" type="Precipitant" span="149 10" str="saquinavir" code="N0000007376"/>
<Mention id="M256" type="Precipitant" span="134 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I115" type="Pharmacokinetic interaction" trigger="M255" precipitant="M240" effect="C54355"/>
<Interaction id="I116" type="Pharmacokinetic interaction" trigger="M255" precipitant="M242" effect="C54355"/>
<Interaction id="I117" type="Pharmacokinetic interaction" trigger="M255" precipitant="M244" effect="C54355"/>
<Interaction id="I118" type="Pharmacokinetic interaction" trigger="M255" precipitant="M246" effect="C54355"/>
<Interaction id="I119" type="Pharmacokinetic interaction" trigger="M255" precipitant="M248" effect="C54355"/>
<Interaction id="I120" type="Pharmacokinetic interaction" trigger="M255" precipitant="M250" effect="C54355"/>
<Interaction id="I121" type="Pharmacokinetic interaction" trigger="M255" precipitant="M252" effect="C54355"/>
<Interaction id="I122" type="Pharmacokinetic interaction" trigger="M255" precipitant="M254" effect="C54355"/>
<Interaction id="I123" type="Pharmacokinetic interaction" trigger="M255" precipitant="M256" effect="C54355"/>
</Sentence>
<Sentence id="171" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.</SentenceText>
<Mention id="M273" type="Trigger" span="248 5;270 8;292 8" str="cause | increase | exposure"/>
<Mention id="M258" type="Precipitant" span="104 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M260" type="Precipitant" span="79 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M262" type="Precipitant" span="120 12" str="itraconazole" code="N0000006753"/>
<Mention id="M264" type="Precipitant" span="39 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M266" type="Precipitant" span="187 10" str="nefazodone" code="N0000007250"/>
<Mention id="M268" type="Precipitant" span="161 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M270" type="Precipitant" span="173 9" str="ritonavir" code="N0000007423"/>
<Mention id="M272" type="Precipitant" span="149 10" str="saquinavir" code="N0000007376"/>
<Mention id="M274" type="Precipitant" span="134 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I124" type="Pharmacokinetic interaction" trigger="M273" precipitant="M258" effect="C54355"/>
<Interaction id="I125" type="Pharmacokinetic interaction" trigger="M273" precipitant="M260" effect="C54355"/>
<Interaction id="I126" type="Pharmacokinetic interaction" trigger="M273" precipitant="M262" effect="C54355"/>
<Interaction id="I127" type="Pharmacokinetic interaction" trigger="M273" precipitant="M264" effect="C54355"/>
<Interaction id="I128" type="Pharmacokinetic interaction" trigger="M273" precipitant="M266" effect="C54355"/>
<Interaction id="I129" type="Pharmacokinetic interaction" trigger="M273" precipitant="M268" effect="C54355"/>
<Interaction id="I130" type="Pharmacokinetic interaction" trigger="M273" precipitant="M270" effect="C54355"/>
<Interaction id="I131" type="Pharmacokinetic interaction" trigger="M273" precipitant="M272" effect="C54355"/>
<Interaction id="I132" type="Pharmacokinetic interaction" trigger="M273" precipitant="M274" effect="C54355"/>
</Sentence>
<Sentence id="171" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.</SentenceText>
<Mention id="M291" type="Trigger" span="248 5;270 8;292 8" str="cause | increase | exposure"/>
<Mention id="M276" type="Precipitant" span="104 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M278" type="Precipitant" span="79 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M280" type="Precipitant" span="120 12" str="itraconazole" code="N0000006753"/>
<Mention id="M282" type="Precipitant" span="39 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M284" type="Precipitant" span="187 10" str="nefazodone" code="N0000007250"/>
<Mention id="M286" type="Precipitant" span="161 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M288" type="Precipitant" span="173 9" str="ritonavir" code="N0000007423"/>
<Mention id="M290" type="Precipitant" span="149 10" str="saquinavir" code="N0000007376"/>
<Mention id="M292" type="Precipitant" span="134 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I133" type="Pharmacokinetic interaction" trigger="M291" precipitant="M276" effect="C54355"/>
<Interaction id="I134" type="Pharmacokinetic interaction" trigger="M291" precipitant="M278" effect="C54355"/>
<Interaction id="I135" type="Pharmacokinetic interaction" trigger="M291" precipitant="M280" effect="C54355"/>
<Interaction id="I136" type="Pharmacokinetic interaction" trigger="M291" precipitant="M282" effect="C54355"/>
<Interaction id="I137" type="Pharmacokinetic interaction" trigger="M291" precipitant="M284" effect="C54355"/>
<Interaction id="I138" type="Pharmacokinetic interaction" trigger="M291" precipitant="M286" effect="C54355"/>
<Interaction id="I139" type="Pharmacokinetic interaction" trigger="M291" precipitant="M288" effect="C54355"/>
<Interaction id="I140" type="Pharmacokinetic interaction" trigger="M291" precipitant="M290" effect="C54355"/>
<Interaction id="I141" type="Pharmacokinetic interaction" trigger="M291" precipitant="M292" effect="C54355"/>
</Sentence>
<Sentence id="171" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.</SentenceText>
<Mention id="M309" type="Trigger" span="248 5;270 8;292 8" str="cause | increase | exposure"/>
<Mention id="M294" type="Precipitant" span="104 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M296" type="Precipitant" span="79 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M298" type="Precipitant" span="120 12" str="itraconazole" code="N0000006753"/>
<Mention id="M300" type="Precipitant" span="39 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M302" type="Precipitant" span="187 10" str="nefazodone" code="N0000007250"/>
<Mention id="M304" type="Precipitant" span="161 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M306" type="Precipitant" span="173 9" str="ritonavir" code="N0000007423"/>
<Mention id="M308" type="Precipitant" span="149 10" str="saquinavir" code="N0000007376"/>
<Mention id="M310" type="Precipitant" span="134 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I142" type="Pharmacokinetic interaction" trigger="M309" precipitant="M294" effect="C54355"/>
<Interaction id="I143" type="Pharmacokinetic interaction" trigger="M309" precipitant="M296" effect="C54355"/>
<Interaction id="I144" type="Pharmacokinetic interaction" trigger="M309" precipitant="M298" effect="C54355"/>
<Interaction id="I145" type="Pharmacokinetic interaction" trigger="M309" precipitant="M300" effect="C54355"/>
<Interaction id="I146" type="Pharmacokinetic interaction" trigger="M309" precipitant="M302" effect="C54355"/>
<Interaction id="I147" type="Pharmacokinetic interaction" trigger="M309" precipitant="M304" effect="C54355"/>
<Interaction id="I148" type="Pharmacokinetic interaction" trigger="M309" precipitant="M306" effect="C54355"/>
<Interaction id="I149" type="Pharmacokinetic interaction" trigger="M309" precipitant="M308" effect="C54355"/>
<Interaction id="I150" type="Pharmacokinetic interaction" trigger="M309" precipitant="M310" effect="C54355"/>
</Sentence>
<Sentence id="171" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.</SentenceText>
<Mention id="M327" type="Trigger" span="248 5;270 8;292 8" str="cause | increase | exposure"/>
<Mention id="M312" type="Precipitant" span="104 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M314" type="Precipitant" span="79 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M316" type="Precipitant" span="120 12" str="itraconazole" code="N0000006753"/>
<Mention id="M318" type="Precipitant" span="39 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M320" type="Precipitant" span="187 10" str="nefazodone" code="N0000007250"/>
<Mention id="M322" type="Precipitant" span="161 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M324" type="Precipitant" span="173 9" str="ritonavir" code="N0000007423"/>
<Mention id="M326" type="Precipitant" span="149 10" str="saquinavir" code="N0000007376"/>
<Mention id="M328" type="Precipitant" span="134 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I151" type="Pharmacokinetic interaction" trigger="M327" precipitant="M312" effect="C54355"/>
<Interaction id="I152" type="Pharmacokinetic interaction" trigger="M327" precipitant="M314" effect="C54355"/>
<Interaction id="I153" type="Pharmacokinetic interaction" trigger="M327" precipitant="M316" effect="C54355"/>
<Interaction id="I154" type="Pharmacokinetic interaction" trigger="M327" precipitant="M318" effect="C54355"/>
<Interaction id="I155" type="Pharmacokinetic interaction" trigger="M327" precipitant="M320" effect="C54355"/>
<Interaction id="I156" type="Pharmacokinetic interaction" trigger="M327" precipitant="M322" effect="C54355"/>
<Interaction id="I157" type="Pharmacokinetic interaction" trigger="M327" precipitant="M324" effect="C54355"/>
<Interaction id="I158" type="Pharmacokinetic interaction" trigger="M327" precipitant="M326" effect="C54355"/>
<Interaction id="I159" type="Pharmacokinetic interaction" trigger="M327" precipitant="M328" effect="C54355"/>
</Sentence>
<Sentence id="171" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.</SentenceText>
<Mention id="M345" type="Trigger" span="248 5;270 8;292 8" str="cause | increase | exposure"/>
<Mention id="M330" type="Precipitant" span="104 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M332" type="Precipitant" span="79 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M334" type="Precipitant" span="120 12" str="itraconazole" code="N0000006753"/>
<Mention id="M336" type="Precipitant" span="39 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M338" type="Precipitant" span="187 10" str="nefazodone" code="N0000007250"/>
<Mention id="M340" type="Precipitant" span="161 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M342" type="Precipitant" span="173 9" str="ritonavir" code="N0000007423"/>
<Mention id="M344" type="Precipitant" span="149 10" str="saquinavir" code="N0000007376"/>
<Mention id="M346" type="Precipitant" span="134 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I160" type="Pharmacokinetic interaction" trigger="M345" precipitant="M330" effect="C54355"/>
<Interaction id="I161" type="Pharmacokinetic interaction" trigger="M345" precipitant="M332" effect="C54355"/>
<Interaction id="I162" type="Pharmacokinetic interaction" trigger="M345" precipitant="M334" effect="C54355"/>
<Interaction id="I163" type="Pharmacokinetic interaction" trigger="M345" precipitant="M336" effect="C54355"/>
<Interaction id="I164" type="Pharmacokinetic interaction" trigger="M345" precipitant="M338" effect="C54355"/>
<Interaction id="I165" type="Pharmacokinetic interaction" trigger="M345" precipitant="M340" effect="C54355"/>
<Interaction id="I166" type="Pharmacokinetic interaction" trigger="M345" precipitant="M342" effect="C54355"/>
<Interaction id="I167" type="Pharmacokinetic interaction" trigger="M345" precipitant="M344" effect="C54355"/>
<Interaction id="I168" type="Pharmacokinetic interaction" trigger="M345" precipitant="M346" effect="C54355"/>
</Sentence>
<Sentence id="171" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.</SentenceText>
<Mention id="M363" type="Trigger" span="248 5;270 8;292 8" str="cause | increase | exposure"/>
<Mention id="M348" type="Precipitant" span="104 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M350" type="Precipitant" span="79 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M352" type="Precipitant" span="120 12" str="itraconazole" code="N0000006753"/>
<Mention id="M354" type="Precipitant" span="39 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M356" type="Precipitant" span="187 10" str="nefazodone" code="N0000007250"/>
<Mention id="M358" type="Precipitant" span="161 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M360" type="Precipitant" span="173 9" str="ritonavir" code="N0000007423"/>
<Mention id="M362" type="Precipitant" span="149 10" str="saquinavir" code="N0000007376"/>
<Mention id="M364" type="Precipitant" span="134 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I169" type="Pharmacokinetic interaction" trigger="M363" precipitant="M348" effect="C54355"/>
<Interaction id="I170" type="Pharmacokinetic interaction" trigger="M363" precipitant="M350" effect="C54355"/>
<Interaction id="I171" type="Pharmacokinetic interaction" trigger="M363" precipitant="M352" effect="C54355"/>
<Interaction id="I172" type="Pharmacokinetic interaction" trigger="M363" precipitant="M354" effect="C54355"/>
<Interaction id="I173" type="Pharmacokinetic interaction" trigger="M363" precipitant="M356" effect="C54355"/>
<Interaction id="I174" type="Pharmacokinetic interaction" trigger="M363" precipitant="M358" effect="C54355"/>
<Interaction id="I175" type="Pharmacokinetic interaction" trigger="M363" precipitant="M360" effect="C54355"/>
<Interaction id="I176" type="Pharmacokinetic interaction" trigger="M363" precipitant="M362" effect="C54355"/>
<Interaction id="I177" type="Pharmacokinetic interaction" trigger="M363" precipitant="M364" effect="C54355"/>
</Sentence>
<Sentence id="171" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.</SentenceText>
<Mention id="M381" type="Trigger" span="248 5;270 8;292 8" str="cause | increase | exposure"/>
<Mention id="M366" type="Precipitant" span="104 14" str="clarithromycin" code="N0000007316"/>
<Mention id="M368" type="Precipitant" span="79 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M370" type="Precipitant" span="120 12" str="itraconazole" code="N0000006753"/>
<Mention id="M372" type="Precipitant" span="39 12" str="ketoconazole" code="N0000007319"/>
<Mention id="M374" type="Precipitant" span="187 10" str="nefazodone" code="N0000007250"/>
<Mention id="M376" type="Precipitant" span="161 10" str="nelfinavir" code="N0000006047"/>
<Mention id="M378" type="Precipitant" span="173 9" str="ritonavir" code="N0000007423"/>
<Mention id="M380" type="Precipitant" span="149 10" str="saquinavir" code="N0000007376"/>
<Mention id="M382" type="Precipitant" span="134 13" str="telithromycin" code="N0000010551"/>
<Interaction id="I178" type="Pharmacokinetic interaction" trigger="M381" precipitant="M366" effect="C54355"/>
<Interaction id="I179" type="Pharmacokinetic interaction" trigger="M381" precipitant="M368" effect="C54355"/>
<Interaction id="I180" type="Pharmacokinetic interaction" trigger="M381" precipitant="M370" effect="C54355"/>
<Interaction id="I181" type="Pharmacokinetic interaction" trigger="M381" precipitant="M372" effect="C54355"/>
<Interaction id="I182" type="Pharmacokinetic interaction" trigger="M381" precipitant="M374" effect="C54355"/>
<Interaction id="I183" type="Pharmacokinetic interaction" trigger="M381" precipitant="M376" effect="C54355"/>
<Interaction id="I184" type="Pharmacokinetic interaction" trigger="M381" precipitant="M378" effect="C54355"/>
<Interaction id="I185" type="Pharmacokinetic interaction" trigger="M381" precipitant="M380" effect="C54355"/>
<Interaction id="I186" type="Pharmacokinetic interaction" trigger="M381" precipitant="M382" effect="C54355"/>
</Sentence>
<Sentence id="172" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with digoxin increased digoxin AUC by 20 % and Cmax by 30 % .</SentenceText>
<Mention id="M383" type="Trigger" span="41 9;75 4" str="increased | Cmax"/>
<Mention id="M386" type="Precipitant" span="33 7" str="digoxin" code="N0000005903"/>
<Mention id="M385" type="Trigger" span="41 9;59 3" str="increased | AUC"/>
<Interaction id="I187" type="Pharmacokinetic interaction" trigger="M383" precipitant="M386" effect="C54610"/>
<Interaction id="I188" type="Pharmacokinetic interaction" trigger="M385" precipitant="M386" effect="C54613"/>
</Sentence>
<Sentence id="172" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with digoxin increased digoxin AUC by 20 % and Cmax by 30 % .</SentenceText>
<Mention id="M387" type="Trigger" span="41 9;75 4" str="increased | Cmax"/>
<Mention id="M390" type="Precipitant" span="33 7" str="digoxin" code="N0000005903"/>
<Mention id="M389" type="Trigger" span="41 9;59 3" str="increased | AUC"/>
<Interaction id="I189" type="Pharmacokinetic interaction" trigger="M387" precipitant="M390" effect="C54610"/>
<Interaction id="I190" type="Pharmacokinetic interaction" trigger="M389" precipitant="M390" effect="C54613"/>
</Sentence>
<Sentence id="173" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of SAMSCA with moderate CYP3A inhibitors should therefore generally be avoided see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.5 ) .</SentenceText>
<Mention id="M391" type="Trigger" span="59 6;86 10" str="should | be avoided"/>
<Mention id="M392" type="Precipitant" span="33 25" str="moderate CYP3A inhibitors" code="n0000191001"/>
<Interaction id="I191" type="Unspecified interaction" trigger="M391" precipitant="M392"/>
</Sentence>
<Sentence id="174" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Co-administration of tolvaptan does not appear to alter the pharmacokinetics of warfarin , furosemide , hydrochlorothiazide , or amiodarone ( or its active metabolite , desethylamiodarone ) to a clinically significant degree .</SentenceText>
</Sentence>
<Sentence id="175" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Concomitant administration of tolvaptan with furosemide or hydrochlorothiazide results in a 24 hour urine volume/excretion rate that is similar to the rate after tolvaptan administration alone .</SentenceText>
</Sentence>
<Sentence id="176" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>CYP 3A Inducers Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment.</SentenceText>
<Mention id="M407" type="Trigger" span="191 12;208 20" str="reduction in | plasma concentration"/>
<Mention id="M394" type="Precipitant" span="99 12" str="barbiturates" code="N0000008016"/>
<Mention id="M396" type="Precipitant" span="124 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M398" type="Precipitant" span="43 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M400" type="Precipitant" span="113 9" str="phenytoin" code="N0000006023"/>
<Mention id="M402" type="Precipitant" span="76 9" str="rifabutin" code="N0000007464"/>
<Mention id="M404" type="Precipitant" span="66 8" str="rifampin" code="N0000006026"/>
<Mention id="M406" type="Precipitant" span="87 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M408" type="Precipitant" span="139 15" str="St. John's Wort" code="N0000022261"/>
<Interaction id="I192" type="Pharmacokinetic interaction" trigger="M407" precipitant="M394" effect="C54356"/>
<Interaction id="I193" type="Pharmacokinetic interaction" trigger="M407" precipitant="M396" effect="C54356"/>
<Interaction id="I194" type="Pharmacokinetic interaction" trigger="M407" precipitant="M398" effect="C54356"/>
<Interaction id="I195" type="Pharmacokinetic interaction" trigger="M407" precipitant="M400" effect="C54356"/>
<Interaction id="I196" type="Pharmacokinetic interaction" trigger="M407" precipitant="M402" effect="C54356"/>
<Interaction id="I197" type="Pharmacokinetic interaction" trigger="M407" precipitant="M404" effect="C54356"/>
<Interaction id="I198" type="Pharmacokinetic interaction" trigger="M407" precipitant="M406" effect="C54356"/>
<Interaction id="I199" type="Pharmacokinetic interaction" trigger="M407" precipitant="M408" effect="C54356"/>
</Sentence>
<Sentence id="176" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>CYP 3A Inducers Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment.</SentenceText>
<Mention id="M423" type="Trigger" span="191 12;208 20" str="reduction in | plasma concentration"/>
<Mention id="M410" type="Precipitant" span="99 12" str="barbiturates" code="N0000008016"/>
<Mention id="M412" type="Precipitant" span="124 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M414" type="Precipitant" span="43 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M416" type="Precipitant" span="113 9" str="phenytoin" code="N0000006023"/>
<Mention id="M418" type="Precipitant" span="76 9" str="rifabutin" code="N0000007464"/>
<Mention id="M420" type="Precipitant" span="66 8" str="rifampin" code="N0000006026"/>
<Mention id="M422" type="Precipitant" span="87 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M424" type="Precipitant" span="139 15" str="St. John's Wort" code="N0000022261"/>
<Interaction id="I200" type="Pharmacokinetic interaction" trigger="M423" precipitant="M410" effect="C54356"/>
<Interaction id="I201" type="Pharmacokinetic interaction" trigger="M423" precipitant="M412" effect="C54356"/>
<Interaction id="I202" type="Pharmacokinetic interaction" trigger="M423" precipitant="M414" effect="C54356"/>
<Interaction id="I203" type="Pharmacokinetic interaction" trigger="M423" precipitant="M416" effect="C54356"/>
<Interaction id="I204" type="Pharmacokinetic interaction" trigger="M423" precipitant="M418" effect="C54356"/>
<Interaction id="I205" type="Pharmacokinetic interaction" trigger="M423" precipitant="M420" effect="C54356"/>
<Interaction id="I206" type="Pharmacokinetic interaction" trigger="M423" precipitant="M422" effect="C54356"/>
<Interaction id="I207" type="Pharmacokinetic interaction" trigger="M423" precipitant="M424" effect="C54356"/>
</Sentence>
<Sentence id="176" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>CYP 3A Inducers Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment.</SentenceText>
<Mention id="M439" type="Trigger" span="191 12;208 20" str="reduction in | plasma concentration"/>
<Mention id="M426" type="Precipitant" span="99 12" str="barbiturates" code="N0000008016"/>
<Mention id="M428" type="Precipitant" span="124 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M430" type="Precipitant" span="43 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M432" type="Precipitant" span="113 9" str="phenytoin" code="N0000006023"/>
<Mention id="M434" type="Precipitant" span="76 9" str="rifabutin" code="N0000007464"/>
<Mention id="M436" type="Precipitant" span="66 8" str="rifampin" code="N0000006026"/>
<Mention id="M438" type="Precipitant" span="87 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M440" type="Precipitant" span="139 15" str="St. John's Wort" code="N0000022261"/>
<Interaction id="I208" type="Pharmacokinetic interaction" trigger="M439" precipitant="M426" effect="C54356"/>
<Interaction id="I209" type="Pharmacokinetic interaction" trigger="M439" precipitant="M428" effect="C54356"/>
<Interaction id="I210" type="Pharmacokinetic interaction" trigger="M439" precipitant="M430" effect="C54356"/>
<Interaction id="I211" type="Pharmacokinetic interaction" trigger="M439" precipitant="M432" effect="C54356"/>
<Interaction id="I212" type="Pharmacokinetic interaction" trigger="M439" precipitant="M434" effect="C54356"/>
<Interaction id="I213" type="Pharmacokinetic interaction" trigger="M439" precipitant="M436" effect="C54356"/>
<Interaction id="I214" type="Pharmacokinetic interaction" trigger="M439" precipitant="M438" effect="C54356"/>
<Interaction id="I215" type="Pharmacokinetic interaction" trigger="M439" precipitant="M440" effect="C54356"/>
</Sentence>
<Sentence id="176" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>CYP 3A Inducers Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment.</SentenceText>
<Mention id="M455" type="Trigger" span="191 12;208 20" str="reduction in | plasma concentration"/>
<Mention id="M442" type="Precipitant" span="99 12" str="barbiturates" code="N0000008016"/>
<Mention id="M444" type="Precipitant" span="124 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M446" type="Precipitant" span="43 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M448" type="Precipitant" span="113 9" str="phenytoin" code="N0000006023"/>
<Mention id="M450" type="Precipitant" span="76 9" str="rifabutin" code="N0000007464"/>
<Mention id="M452" type="Precipitant" span="66 8" str="rifampin" code="N0000006026"/>
<Mention id="M454" type="Precipitant" span="87 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M456" type="Precipitant" span="139 15" str="St. John's Wort" code="N0000022261"/>
<Interaction id="I216" type="Pharmacokinetic interaction" trigger="M455" precipitant="M442" effect="C54356"/>
<Interaction id="I217" type="Pharmacokinetic interaction" trigger="M455" precipitant="M444" effect="C54356"/>
<Interaction id="I218" type="Pharmacokinetic interaction" trigger="M455" precipitant="M446" effect="C54356"/>
<Interaction id="I219" type="Pharmacokinetic interaction" trigger="M455" precipitant="M448" effect="C54356"/>
<Interaction id="I220" type="Pharmacokinetic interaction" trigger="M455" precipitant="M450" effect="C54356"/>
<Interaction id="I221" type="Pharmacokinetic interaction" trigger="M455" precipitant="M452" effect="C54356"/>
<Interaction id="I222" type="Pharmacokinetic interaction" trigger="M455" precipitant="M454" effect="C54356"/>
<Interaction id="I223" type="Pharmacokinetic interaction" trigger="M455" precipitant="M456" effect="C54356"/>
</Sentence>
<Sentence id="176" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>CYP 3A Inducers Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment.</SentenceText>
<Mention id="M471" type="Trigger" span="191 12;208 20" str="reduction in | plasma concentration"/>
<Mention id="M458" type="Precipitant" span="99 12" str="barbiturates" code="N0000008016"/>
<Mention id="M460" type="Precipitant" span="124 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M462" type="Precipitant" span="43 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M464" type="Precipitant" span="113 9" str="phenytoin" code="N0000006023"/>
<Mention id="M466" type="Precipitant" span="76 9" str="rifabutin" code="N0000007464"/>
<Mention id="M468" type="Precipitant" span="66 8" str="rifampin" code="N0000006026"/>
<Mention id="M470" type="Precipitant" span="87 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M472" type="Precipitant" span="139 15" str="St. John's Wort" code="N0000022261"/>
<Interaction id="I224" type="Pharmacokinetic interaction" trigger="M471" precipitant="M458" effect="C54356"/>
<Interaction id="I225" type="Pharmacokinetic interaction" trigger="M471" precipitant="M460" effect="C54356"/>
<Interaction id="I226" type="Pharmacokinetic interaction" trigger="M471" precipitant="M462" effect="C54356"/>
<Interaction id="I227" type="Pharmacokinetic interaction" trigger="M471" precipitant="M464" effect="C54356"/>
<Interaction id="I228" type="Pharmacokinetic interaction" trigger="M471" precipitant="M466" effect="C54356"/>
<Interaction id="I229" type="Pharmacokinetic interaction" trigger="M471" precipitant="M468" effect="C54356"/>
<Interaction id="I230" type="Pharmacokinetic interaction" trigger="M471" precipitant="M470" effect="C54356"/>
<Interaction id="I231" type="Pharmacokinetic interaction" trigger="M471" precipitant="M472" effect="C54356"/>
</Sentence>
<Sentence id="176" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>CYP 3A Inducers Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment.</SentenceText>
<Mention id="M487" type="Trigger" span="191 12;208 20" str="reduction in | plasma concentration"/>
<Mention id="M474" type="Precipitant" span="99 12" str="barbiturates" code="N0000008016"/>
<Mention id="M476" type="Precipitant" span="124 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M478" type="Precipitant" span="43 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M480" type="Precipitant" span="113 9" str="phenytoin" code="N0000006023"/>
<Mention id="M482" type="Precipitant" span="76 9" str="rifabutin" code="N0000007464"/>
<Mention id="M484" type="Precipitant" span="66 8" str="rifampin" code="N0000006026"/>
<Mention id="M486" type="Precipitant" span="87 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M488" type="Precipitant" span="139 15" str="St. John's Wort" code="N0000022261"/>
<Interaction id="I232" type="Pharmacokinetic interaction" trigger="M487" precipitant="M474" effect="C54356"/>
<Interaction id="I233" type="Pharmacokinetic interaction" trigger="M487" precipitant="M476" effect="C54356"/>
<Interaction id="I234" type="Pharmacokinetic interaction" trigger="M487" precipitant="M478" effect="C54356"/>
<Interaction id="I235" type="Pharmacokinetic interaction" trigger="M487" precipitant="M480" effect="C54356"/>
<Interaction id="I236" type="Pharmacokinetic interaction" trigger="M487" precipitant="M482" effect="C54356"/>
<Interaction id="I237" type="Pharmacokinetic interaction" trigger="M487" precipitant="M484" effect="C54356"/>
<Interaction id="I238" type="Pharmacokinetic interaction" trigger="M487" precipitant="M486" effect="C54356"/>
<Interaction id="I239" type="Pharmacokinetic interaction" trigger="M487" precipitant="M488" effect="C54356"/>
</Sentence>
<Sentence id="176" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>CYP 3A Inducers Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment.</SentenceText>
<Mention id="M503" type="Trigger" span="191 12;208 20" str="reduction in | plasma concentration"/>
<Mention id="M490" type="Precipitant" span="99 12" str="barbiturates" code="N0000008016"/>
<Mention id="M492" type="Precipitant" span="124 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M494" type="Precipitant" span="43 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M496" type="Precipitant" span="113 9" str="phenytoin" code="N0000006023"/>
<Mention id="M498" type="Precipitant" span="76 9" str="rifabutin" code="N0000007464"/>
<Mention id="M500" type="Precipitant" span="66 8" str="rifampin" code="N0000006026"/>
<Mention id="M502" type="Precipitant" span="87 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M504" type="Precipitant" span="139 15" str="St. John's Wort" code="N0000022261"/>
<Interaction id="I240" type="Pharmacokinetic interaction" trigger="M503" precipitant="M490" effect="C54356"/>
<Interaction id="I241" type="Pharmacokinetic interaction" trigger="M503" precipitant="M492" effect="C54356"/>
<Interaction id="I242" type="Pharmacokinetic interaction" trigger="M503" precipitant="M494" effect="C54356"/>
<Interaction id="I243" type="Pharmacokinetic interaction" trigger="M503" precipitant="M496" effect="C54356"/>
<Interaction id="I244" type="Pharmacokinetic interaction" trigger="M503" precipitant="M498" effect="C54356"/>
<Interaction id="I245" type="Pharmacokinetic interaction" trigger="M503" precipitant="M500" effect="C54356"/>
<Interaction id="I246" type="Pharmacokinetic interaction" trigger="M503" precipitant="M502" effect="C54356"/>
<Interaction id="I247" type="Pharmacokinetic interaction" trigger="M503" precipitant="M504" effect="C54356"/>
</Sentence>
<Sentence id="176" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>CYP 3A Inducers Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment.</SentenceText>
<Mention id="M519" type="Trigger" span="191 12;208 20" str="reduction in | plasma concentration"/>
<Mention id="M506" type="Precipitant" span="99 12" str="barbiturates" code="N0000008016"/>
<Mention id="M508" type="Precipitant" span="124 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M510" type="Precipitant" span="43 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M512" type="Precipitant" span="113 9" str="phenytoin" code="N0000006023"/>
<Mention id="M514" type="Precipitant" span="76 9" str="rifabutin" code="N0000007464"/>
<Mention id="M516" type="Precipitant" span="66 8" str="rifampin" code="N0000006026"/>
<Mention id="M518" type="Precipitant" span="87 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M520" type="Precipitant" span="139 15" str="St. John's Wort" code="N0000022261"/>
<Interaction id="I248" type="Pharmacokinetic interaction" trigger="M519" precipitant="M506" effect="C54356"/>
<Interaction id="I249" type="Pharmacokinetic interaction" trigger="M519" precipitant="M508" effect="C54356"/>
<Interaction id="I250" type="Pharmacokinetic interaction" trigger="M519" precipitant="M510" effect="C54356"/>
<Interaction id="I251" type="Pharmacokinetic interaction" trigger="M519" precipitant="M512" effect="C54356"/>
<Interaction id="I252" type="Pharmacokinetic interaction" trigger="M519" precipitant="M514" effect="C54356"/>
<Interaction id="I253" type="Pharmacokinetic interaction" trigger="M519" precipitant="M516" effect="C54356"/>
<Interaction id="I254" type="Pharmacokinetic interaction" trigger="M519" precipitant="M518" effect="C54356"/>
<Interaction id="I255" type="Pharmacokinetic interaction" trigger="M519" precipitant="M520" effect="C54356"/>
</Sentence>
<Sentence id="177" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>CYP 3A inhibitors can lead to a marked increase in tolvaptan concentrations [see Dosage and Administration (2.3), Drug Interactions (7.1)].</SentenceText>
<Mention id="M521" type="Trigger" span="39 8;61 13" str="increase | concentration"/>
<Mention id="M522" type="Precipitant" span="0 17" str="CYP 3A inhibitors" code="n0000191001"/>
<Interaction id="I256" type="Pharmacokinetic interaction" trigger="M521" precipitant="M522" effect="C54355"/>
</Sentence>
<Sentence id="178" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Do not use SAMSCA with strong inhibitors of CYP 3A [see Contraindications (4.4)] and avoid concomitant use with moderate CYP 3A inhibitors.</SentenceText>
<Mention id="M523" type="Trigger" span="85 5" str="avoid"/>
<Mention id="M524" type="Precipitant" span="112 26" str="moderate CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M525" type="Trigger" span="0 10" str="Do not use"/>
<Mention id="M526" type="Precipitant" span="23 27" str="strong inhibitors of CYP 3A" code="n0000191001"/>
<Interaction id="I257" type="Unspecified interaction" trigger="M523" precipitant="M524"/>
<Interaction id="I258" type="Unspecified interaction" trigger="M525" precipitant="M526"/>
</Sentence>
<Sentence id="178" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Do not use SAMSCA with strong inhibitors of CYP 3A [see Contraindications (4.4)] and avoid concomitant use with moderate CYP 3A inhibitors.</SentenceText>
<Mention id="M527" type="Trigger" span="85 5" str="avoid"/>
<Mention id="M528" type="Precipitant" span="112 26" str="moderate CYP 3A inhibitors" code="n0000191001"/>
<Mention id="M529" type="Trigger" span="0 10" str="Do not use"/>
<Mention id="M530" type="Precipitant" span="23 27" str="strong inhibitors of CYP 3A" code="n0000191001"/>
<Interaction id="I259" type="Unspecified interaction" trigger="M527" precipitant="M528"/>
<Interaction id="I260" type="Unspecified interaction" trigger="M529" precipitant="M530"/>
</Sentence>
<Sentence id="179" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Grapefruit Juice Co-administration of grapefruit juice and SAMSCA results in a 1.8-fold increase in exposure to tolvaptan [see Dose and Administration (2.3) and Warnings and Precautions (5.5)].</SentenceText>
</Sentence>
<Sentence id="180" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>If co-administered with CYP 3A inducers, the dose of SAMSCA may need to be increased [see Dosage and Administration (2.3), Drug Interactions (7.1)].</SentenceText>
<Mention id="M531" type="Trigger" span="45 4;75 9" str="dose | increased"/>
<Mention id="M532" type="Precipitant" span="24 15" str="CYP 3A inducers" code="n0000190118"/>
<Interaction id="I261" type="Unspecified interaction" trigger="M531" precipitant="M532"/>
</Sentence>
<Sentence id="181" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>In a male subject with mild Von Willebrand ( vW ) disease , intravenous infusion of dDAVP 2 hours after administration of oral tolvaptan did not produce the expected increases in vW Factor Antigen or Factor VIII activity .</SentenceText>
</Sentence>
<Sentence id="182" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>In a male subject with mild Von Willebrand (vW) disease, intravenous infusion of dDAVP 2 hours after administration of oral tolvaptan did not produce the expected increases in vW Factor Antigen or Factor VIII activity.</SentenceText>
</Sentence>
<Sentence id="183" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>It is not recommended to administer SAMSCA with a V2-agonist.</SentenceText>
<Mention id="M533" type="Trigger" span="6 15" str="not recommended"/>
<Mention id="M534" type="Precipitant" span="50 10" str="V2-agonist" code="NO MAP"/>
<Interaction id="I262" type="Unspecified interaction" trigger="M533" precipitant="M534"/>
</Sentence>
<Sentence id="184" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Ketoconazole and Other Strong CYP 3A Inhibitors SAMSCA is metabolized primarily by CYP 3A.</SentenceText>
</Sentence>
<Sentence id="185" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Ketoconazole is a strong inhibitor of CYP 3A and also an inhibitor of P-gp.</SentenceText>
</Sentence>
<Sentence id="186" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Lovastatin SAMSCA is a weak inhibitor of CYP 3A.</SentenceText>
</Sentence>
<Sentence id="187" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Lovastatin, Digoxin, Furosemide, and Hydrochlorothiazide Co-administration of lovastatin, digoxin, furosemide, and hydrochlorothiazide with SAMSCA has no clinically relevant impact on the exposure to tolvaptan.</SentenceText>
</Sentence>
<Sentence id="188" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Moderate CYP 3A Inhibitors The impact of moderate CYP 3A inhibitors (e.g., erythromycin, fluconazole, aprepitant, diltiazem and verapamil) on the exposure to co-administered tolvaptan has not been assessed.</SentenceText>
</Sentence>
<Sentence id="189" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Other Drugs Affecting Exposure to Tolvaptan CYP 3A Inhibitors Tolvaptan is a substrate of CYP 3A.</SentenceText>
</Sentence>
<Sentence id="190" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>P-gp Inhibitors Reduction in the dose of SAMSCA may be required in patients concomitantly treated with P-gp inhibitors, such as e.g., cyclosporine, based on clinical response [see Dose and Administration (2.3) and Warnings and Precautions (5.5)].</SentenceText>
<Mention id="M537" type="Trigger" span="16 12;33 4" str="Reduction in | dose"/>
<Mention id="M536" type="Precipitant" span="134 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M538" type="Precipitant" span="103 15" str="P-gp inhibitors" code="n0000185503"/>
<Interaction id="I263" type="Unspecified interaction" trigger="M537" precipitant="M536"/>
<Interaction id="I264" type="Unspecified interaction" trigger="M537" precipitant="M538"/>
</Sentence>
<Sentence id="190" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>P-gp Inhibitors Reduction in the dose of SAMSCA may be required in patients concomitantly treated with P-gp inhibitors, such as e.g., cyclosporine, based on clinical response [see Dose and Administration (2.3) and Warnings and Precautions (5.5)].</SentenceText>
<Mention id="M541" type="Trigger" span="16 12;33 4" str="Reduction in | dose"/>
<Mention id="M540" type="Precipitant" span="134 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M542" type="Precipitant" span="103 15" str="P-gp inhibitors" code="n0000185503"/>
<Interaction id="I265" type="Unspecified interaction" trigger="M541" precipitant="M540"/>
<Interaction id="I266" type="Unspecified interaction" trigger="M541" precipitant="M542"/>
</Sentence>
<Sentence id="191" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>P-gp Inhibitors The dose of SAMSCA may have to be reduced when SAMSCA is co-administered with P-gp inhibitors, e.g., cyclosporine [see Dosage and Administration (2.3), Drug Interactions (7.1)].</SentenceText>
<Mention id="M545" type="Trigger" span="20 4;35 22" str="dose | may have to be reduced"/>
<Mention id="M544" type="Precipitant" span="117 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M546" type="Precipitant" span="94 15" str="P-gp inhibitors" code="n0000185503"/>
<Interaction id="I267" type="Unspecified interaction" trigger="M545" precipitant="M544"/>
<Interaction id="I268" type="Unspecified interaction" trigger="M545" precipitant="M546"/>
</Sentence>
<Sentence id="191" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>P-gp Inhibitors The dose of SAMSCA may have to be reduced when SAMSCA is co-administered with P-gp inhibitors, e.g., cyclosporine [see Dosage and Administration (2.3), Drug Interactions (7.1)].</SentenceText>
<Mention id="M549" type="Trigger" span="20 4;35 22" str="dose | may have to be reduced"/>
<Mention id="M548" type="Precipitant" span="117 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M550" type="Precipitant" span="94 15" str="P-gp inhibitors" code="n0000185503"/>
<Interaction id="I269" type="Unspecified interaction" trigger="M549" precipitant="M548"/>
<Interaction id="I270" type="Unspecified interaction" trigger="M549" precipitant="M550"/>
</Sentence>
<Sentence id="192" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Pharmacodynamic Interactions Tolvaptan produces a greater 24hour urine volume/excretion rate than does furosemide or hydrochlorothiazide.</SentenceText>
</Sentence>
<Sentence id="193" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Reduction in the dose of SAMSCA may be required in patients concomitantly treated with P-gp inhibitors , such as e.g. , cyclosporine , based on clinical response see Dose and Administration ( 2.3 ) and Warnings and Precautions ( 5.5 ) .</SentenceText>
<Mention id="M553" type="Trigger" span="0 12;17 4" str="Reduction in | dose"/>
<Mention id="M552" type="Precipitant" span="120 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M554" type="Precipitant" span="87 15" str="P-gp inhibitors" code="n0000185503"/>
<Interaction id="I271" type="Unspecified interaction" trigger="M553" precipitant="M552"/>
<Interaction id="I272" type="Unspecified interaction" trigger="M553" precipitant="M554"/>
</Sentence>
<Sentence id="193" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Reduction in the dose of SAMSCA may be required in patients concomitantly treated with P-gp inhibitors , such as e.g. , cyclosporine , based on clinical response see Dose and Administration ( 2.3 ) and Warnings and Precautions ( 5.5 ) .</SentenceText>
<Mention id="M557" type="Trigger" span="0 12;17 4" str="Reduction in | dose"/>
<Mention id="M556" type="Precipitant" span="120 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M558" type="Precipitant" span="87 15" str="P-gp inhibitors" code="n0000185503"/>
<Interaction id="I273" type="Unspecified interaction" trigger="M557" precipitant="M556"/>
<Interaction id="I274" type="Unspecified interaction" trigger="M557" precipitant="M558"/>
</Sentence>
<Sentence id="194" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Rifampin and Other CYP 3A Inducers Rifampin is an inducer of CYP 3A and P-gp.</SentenceText>
</Sentence>
<Sentence id="195" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Serum potassium levels should be monitored during concomitant drug therapy.</SentenceText>
</Sentence>
<Sentence id="196" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>The dose of SAMSCA may have to be increased [Dosage and Administration (2.3) and Warnings and Precautions (5.5)].</SentenceText>
</Sentence>
<Sentence id="197" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>The impact of moderate CYP 3A inhibitors ( e.g. , erythromycin , fluconazole , aprepitant , diltiazem and verapamil ) on the exposure to co-administered tolvaptan has not been assessed .</SentenceText>
</Sentence>
<Sentence id="198" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Therefore , the expected clinical effects of SAMSCA in the presence of rifampin and other inducers ( e.g. , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine and St.   John 's   Wort ) may not be observed at the usual dose levels of SAMSCA .</SentenceText>
<Mention id="M573" type="Trigger" span="25 16;201 19" str="clinical effects | may not be observed"/>
<Mention id="M560" type="Precipitant" span="133 12" str="barbiturates" code="N0000008016"/>
<Mention id="M562" type="Precipitant" span="160 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M564" type="Precipitant" span="90 8" str="inducers" code="NO MAP"/>
<Mention id="M566" type="Precipitant" span="148 9" str="phenytoin" code="N0000006023"/>
<Mention id="M568" type="Precipitant" span="108 9" str="rifabutin" code="N0000007464"/>
<Mention id="M570" type="Precipitant" span="71 8" str="rifampin" code="N0000006026"/>
<Mention id="M572" type="Precipitant" span="120 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M574" type="Precipitant" span="178 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I275" type="Unspecified interaction" trigger="M573" precipitant="M560"/>
<Interaction id="I276" type="Unspecified interaction" trigger="M573" precipitant="M562"/>
<Interaction id="I277" type="Unspecified interaction" trigger="M573" precipitant="M564"/>
<Interaction id="I278" type="Unspecified interaction" trigger="M573" precipitant="M566"/>
<Interaction id="I279" type="Unspecified interaction" trigger="M573" precipitant="M568"/>
<Interaction id="I280" type="Unspecified interaction" trigger="M573" precipitant="M570"/>
<Interaction id="I281" type="Unspecified interaction" trigger="M573" precipitant="M572"/>
<Interaction id="I282" type="Unspecified interaction" trigger="M573" precipitant="M574"/>
</Sentence>
<Sentence id="198" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Therefore , the expected clinical effects of SAMSCA in the presence of rifampin and other inducers ( e.g. , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine and St.   John 's   Wort ) may not be observed at the usual dose levels of SAMSCA .</SentenceText>
<Mention id="M589" type="Trigger" span="25 16;201 19" str="clinical effects | may not be observed"/>
<Mention id="M576" type="Precipitant" span="133 12" str="barbiturates" code="N0000008016"/>
<Mention id="M578" type="Precipitant" span="160 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M580" type="Precipitant" span="90 8" str="inducers" code="NO MAP"/>
<Mention id="M582" type="Precipitant" span="148 9" str="phenytoin" code="N0000006023"/>
<Mention id="M584" type="Precipitant" span="108 9" str="rifabutin" code="N0000007464"/>
<Mention id="M586" type="Precipitant" span="71 8" str="rifampin" code="N0000006026"/>
<Mention id="M588" type="Precipitant" span="120 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M590" type="Precipitant" span="178 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I283" type="Unspecified interaction" trigger="M589" precipitant="M576"/>
<Interaction id="I284" type="Unspecified interaction" trigger="M589" precipitant="M578"/>
<Interaction id="I285" type="Unspecified interaction" trigger="M589" precipitant="M580"/>
<Interaction id="I286" type="Unspecified interaction" trigger="M589" precipitant="M582"/>
<Interaction id="I287" type="Unspecified interaction" trigger="M589" precipitant="M584"/>
<Interaction id="I288" type="Unspecified interaction" trigger="M589" precipitant="M586"/>
<Interaction id="I289" type="Unspecified interaction" trigger="M589" precipitant="M588"/>
<Interaction id="I290" type="Unspecified interaction" trigger="M589" precipitant="M590"/>
</Sentence>
<Sentence id="198" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Therefore , the expected clinical effects of SAMSCA in the presence of rifampin and other inducers ( e.g. , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine and St.   John 's   Wort ) may not be observed at the usual dose levels of SAMSCA .</SentenceText>
<Mention id="M605" type="Trigger" span="25 16;201 19" str="clinical effects | may not be observed"/>
<Mention id="M592" type="Precipitant" span="133 12" str="barbiturates" code="N0000008016"/>
<Mention id="M594" type="Precipitant" span="160 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M596" type="Precipitant" span="90 8" str="inducers" code="NO MAP"/>
<Mention id="M598" type="Precipitant" span="148 9" str="phenytoin" code="N0000006023"/>
<Mention id="M600" type="Precipitant" span="108 9" str="rifabutin" code="N0000007464"/>
<Mention id="M602" type="Precipitant" span="71 8" str="rifampin" code="N0000006026"/>
<Mention id="M604" type="Precipitant" span="120 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M606" type="Precipitant" span="178 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I291" type="Unspecified interaction" trigger="M605" precipitant="M592"/>
<Interaction id="I292" type="Unspecified interaction" trigger="M605" precipitant="M594"/>
<Interaction id="I293" type="Unspecified interaction" trigger="M605" precipitant="M596"/>
<Interaction id="I294" type="Unspecified interaction" trigger="M605" precipitant="M598"/>
<Interaction id="I295" type="Unspecified interaction" trigger="M605" precipitant="M600"/>
<Interaction id="I296" type="Unspecified interaction" trigger="M605" precipitant="M602"/>
<Interaction id="I297" type="Unspecified interaction" trigger="M605" precipitant="M604"/>
<Interaction id="I298" type="Unspecified interaction" trigger="M605" precipitant="M606"/>
</Sentence>
<Sentence id="198" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Therefore , the expected clinical effects of SAMSCA in the presence of rifampin and other inducers ( e.g. , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine and St.   John 's   Wort ) may not be observed at the usual dose levels of SAMSCA .</SentenceText>
<Mention id="M621" type="Trigger" span="25 16;201 19" str="clinical effects | may not be observed"/>
<Mention id="M608" type="Precipitant" span="133 12" str="barbiturates" code="N0000008016"/>
<Mention id="M610" type="Precipitant" span="160 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M612" type="Precipitant" span="90 8" str="inducers" code="NO MAP"/>
<Mention id="M614" type="Precipitant" span="148 9" str="phenytoin" code="N0000006023"/>
<Mention id="M616" type="Precipitant" span="108 9" str="rifabutin" code="N0000007464"/>
<Mention id="M618" type="Precipitant" span="71 8" str="rifampin" code="N0000006026"/>
<Mention id="M620" type="Precipitant" span="120 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M622" type="Precipitant" span="178 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I299" type="Unspecified interaction" trigger="M621" precipitant="M608"/>
<Interaction id="I300" type="Unspecified interaction" trigger="M621" precipitant="M610"/>
<Interaction id="I301" type="Unspecified interaction" trigger="M621" precipitant="M612"/>
<Interaction id="I302" type="Unspecified interaction" trigger="M621" precipitant="M614"/>
<Interaction id="I303" type="Unspecified interaction" trigger="M621" precipitant="M616"/>
<Interaction id="I304" type="Unspecified interaction" trigger="M621" precipitant="M618"/>
<Interaction id="I305" type="Unspecified interaction" trigger="M621" precipitant="M620"/>
<Interaction id="I306" type="Unspecified interaction" trigger="M621" precipitant="M622"/>
</Sentence>
<Sentence id="198" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Therefore , the expected clinical effects of SAMSCA in the presence of rifampin and other inducers ( e.g. , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine and St.   John 's   Wort ) may not be observed at the usual dose levels of SAMSCA .</SentenceText>
<Mention id="M637" type="Trigger" span="25 16;201 19" str="clinical effects | may not be observed"/>
<Mention id="M624" type="Precipitant" span="133 12" str="barbiturates" code="N0000008016"/>
<Mention id="M626" type="Precipitant" span="160 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M628" type="Precipitant" span="90 8" str="inducers" code="NO MAP"/>
<Mention id="M630" type="Precipitant" span="148 9" str="phenytoin" code="N0000006023"/>
<Mention id="M632" type="Precipitant" span="108 9" str="rifabutin" code="N0000007464"/>
<Mention id="M634" type="Precipitant" span="71 8" str="rifampin" code="N0000006026"/>
<Mention id="M636" type="Precipitant" span="120 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M638" type="Precipitant" span="178 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I307" type="Unspecified interaction" trigger="M637" precipitant="M624"/>
<Interaction id="I308" type="Unspecified interaction" trigger="M637" precipitant="M626"/>
<Interaction id="I309" type="Unspecified interaction" trigger="M637" precipitant="M628"/>
<Interaction id="I310" type="Unspecified interaction" trigger="M637" precipitant="M630"/>
<Interaction id="I311" type="Unspecified interaction" trigger="M637" precipitant="M632"/>
<Interaction id="I312" type="Unspecified interaction" trigger="M637" precipitant="M634"/>
<Interaction id="I313" type="Unspecified interaction" trigger="M637" precipitant="M636"/>
<Interaction id="I314" type="Unspecified interaction" trigger="M637" precipitant="M638"/>
</Sentence>
<Sentence id="198" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Therefore , the expected clinical effects of SAMSCA in the presence of rifampin and other inducers ( e.g. , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine and St.   John 's   Wort ) may not be observed at the usual dose levels of SAMSCA .</SentenceText>
<Mention id="M653" type="Trigger" span="25 16;201 19" str="clinical effects | may not be observed"/>
<Mention id="M640" type="Precipitant" span="133 12" str="barbiturates" code="N0000008016"/>
<Mention id="M642" type="Precipitant" span="160 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M644" type="Precipitant" span="90 8" str="inducers" code="NO MAP"/>
<Mention id="M646" type="Precipitant" span="148 9" str="phenytoin" code="N0000006023"/>
<Mention id="M648" type="Precipitant" span="108 9" str="rifabutin" code="N0000007464"/>
<Mention id="M650" type="Precipitant" span="71 8" str="rifampin" code="N0000006026"/>
<Mention id="M652" type="Precipitant" span="120 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M654" type="Precipitant" span="178 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I315" type="Unspecified interaction" trigger="M653" precipitant="M640"/>
<Interaction id="I316" type="Unspecified interaction" trigger="M653" precipitant="M642"/>
<Interaction id="I317" type="Unspecified interaction" trigger="M653" precipitant="M644"/>
<Interaction id="I318" type="Unspecified interaction" trigger="M653" precipitant="M646"/>
<Interaction id="I319" type="Unspecified interaction" trigger="M653" precipitant="M648"/>
<Interaction id="I320" type="Unspecified interaction" trigger="M653" precipitant="M650"/>
<Interaction id="I321" type="Unspecified interaction" trigger="M653" precipitant="M652"/>
<Interaction id="I322" type="Unspecified interaction" trigger="M653" precipitant="M654"/>
</Sentence>
<Sentence id="198" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Therefore , the expected clinical effects of SAMSCA in the presence of rifampin and other inducers ( e.g. , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine and St.   John 's   Wort ) may not be observed at the usual dose levels of SAMSCA .</SentenceText>
<Mention id="M669" type="Trigger" span="25 16;201 19" str="clinical effects | may not be observed"/>
<Mention id="M656" type="Precipitant" span="133 12" str="barbiturates" code="N0000008016"/>
<Mention id="M658" type="Precipitant" span="160 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M660" type="Precipitant" span="90 8" str="inducers" code="NO MAP"/>
<Mention id="M662" type="Precipitant" span="148 9" str="phenytoin" code="N0000006023"/>
<Mention id="M664" type="Precipitant" span="108 9" str="rifabutin" code="N0000007464"/>
<Mention id="M666" type="Precipitant" span="71 8" str="rifampin" code="N0000006026"/>
<Mention id="M668" type="Precipitant" span="120 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M670" type="Precipitant" span="178 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I323" type="Unspecified interaction" trigger="M669" precipitant="M656"/>
<Interaction id="I324" type="Unspecified interaction" trigger="M669" precipitant="M658"/>
<Interaction id="I325" type="Unspecified interaction" trigger="M669" precipitant="M660"/>
<Interaction id="I326" type="Unspecified interaction" trigger="M669" precipitant="M662"/>
<Interaction id="I327" type="Unspecified interaction" trigger="M669" precipitant="M664"/>
<Interaction id="I328" type="Unspecified interaction" trigger="M669" precipitant="M666"/>
<Interaction id="I329" type="Unspecified interaction" trigger="M669" precipitant="M668"/>
<Interaction id="I330" type="Unspecified interaction" trigger="M669" precipitant="M670"/>
</Sentence>
<Sentence id="198" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Therefore , the expected clinical effects of SAMSCA in the presence of rifampin and other inducers ( e.g. , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine and St.   John 's   Wort ) may not be observed at the usual dose levels of SAMSCA .</SentenceText>
<Mention id="M685" type="Trigger" span="25 16;201 19" str="clinical effects | may not be observed"/>
<Mention id="M672" type="Precipitant" span="133 12" str="barbiturates" code="N0000008016"/>
<Mention id="M674" type="Precipitant" span="160 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M676" type="Precipitant" span="90 8" str="inducers" code="NO MAP"/>
<Mention id="M678" type="Precipitant" span="148 9" str="phenytoin" code="N0000006023"/>
<Mention id="M680" type="Precipitant" span="108 9" str="rifabutin" code="N0000007464"/>
<Mention id="M682" type="Precipitant" span="71 8" str="rifampin" code="N0000006026"/>
<Mention id="M684" type="Precipitant" span="120 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M686" type="Precipitant" span="178 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I331" type="Unspecified interaction" trigger="M685" precipitant="M672"/>
<Interaction id="I332" type="Unspecified interaction" trigger="M685" precipitant="M674"/>
<Interaction id="I333" type="Unspecified interaction" trigger="M685" precipitant="M676"/>
<Interaction id="I334" type="Unspecified interaction" trigger="M685" precipitant="M678"/>
<Interaction id="I335" type="Unspecified interaction" trigger="M685" precipitant="M680"/>
<Interaction id="I336" type="Unspecified interaction" trigger="M685" precipitant="M682"/>
<Interaction id="I337" type="Unspecified interaction" trigger="M685" precipitant="M684"/>
<Interaction id="I338" type="Unspecified interaction" trigger="M685" precipitant="M686"/>
</Sentence>
<Sentence id="199" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>This is not a clinically relevant change.</SentenceText>
</Sentence>
<Sentence id="200" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Thus, SAMSCA and strong CYP 3A inhibitors should not be co-administered [see Dosage and Administration (2.3) and Contraindications (4.4)].</SentenceText>
<Mention id="M687" type="Trigger" span="42 29" str="should not be co-administered"/>
<Mention id="M688" type="Precipitant" span="17 24" str="strong CYP 3A inhibitors" code="n00001910011"/>
<Interaction id="I339" type="Unspecified interaction" trigger="M687" precipitant="M688"/>
</Sentence>
<Sentence id="201" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Tolvaptan produces a greater 24 hour urine volume/excretion rate than does furosemide or hydrochlorothiazide .</SentenceText>
</Sentence>
<Sentence id="202" LabelDrug="SAMSCA" section="34073-7">
<SentenceText>Warfarin, Amiodarone, Furosemide, and Hydrochlorothiazide Co-administration of tolvaptan does not appear to alter the pharmacokinetics of warfarin, furosemide, hydrochlorothiazide, or amiodarone (or its active metabolite, desethylamiodarone) to a clinically significant degree.</SentenceText>
</Sentence>
<Sentence id="203" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>Avoid co-administration of CYP 3A inducers ( e.g. , rifampin , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine , St.   John 's   Wort ) with SAMSCA , as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment .</SentenceText>
<Mention id="M703" type="Trigger" span="190 12;207 20" str="reduction in | plasma concentration"/>
<Mention id="M690" type="Precipitant" span="88 12" str="barbiturates" code="N0000008016"/>
<Mention id="M692" type="Precipitant" span="115 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M694" type="Precipitant" span="27 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M696" type="Precipitant" span="103 9" str="phenytoin" code="N0000006023"/>
<Mention id="M698" type="Precipitant" span="63 9" str="rifabutin" code="N0000007464"/>
<Mention id="M700" type="Precipitant" span="52 8" str="rifampin" code="N0000006026"/>
<Mention id="M702" type="Precipitant" span="75 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M704" type="Precipitant" span="131 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I340" type="Pharmacokinetic interaction" trigger="M703" precipitant="M690" effect="C54356"/>
<Interaction id="I341" type="Pharmacokinetic interaction" trigger="M703" precipitant="M692" effect="C54356"/>
<Interaction id="I342" type="Pharmacokinetic interaction" trigger="M703" precipitant="M694" effect="C54356"/>
<Interaction id="I343" type="Pharmacokinetic interaction" trigger="M703" precipitant="M696" effect="C54356"/>
<Interaction id="I344" type="Pharmacokinetic interaction" trigger="M703" precipitant="M698" effect="C54356"/>
<Interaction id="I345" type="Pharmacokinetic interaction" trigger="M703" precipitant="M700" effect="C54356"/>
<Interaction id="I346" type="Pharmacokinetic interaction" trigger="M703" precipitant="M702" effect="C54356"/>
<Interaction id="I347" type="Pharmacokinetic interaction" trigger="M703" precipitant="M704" effect="C54356"/>
</Sentence>
<Sentence id="203" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>Avoid co-administration of CYP 3A inducers ( e.g. , rifampin , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine , St.   John 's   Wort ) with SAMSCA , as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment .</SentenceText>
<Mention id="M719" type="Trigger" span="190 12;207 20" str="reduction in | plasma concentration"/>
<Mention id="M706" type="Precipitant" span="88 12" str="barbiturates" code="N0000008016"/>
<Mention id="M708" type="Precipitant" span="115 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M710" type="Precipitant" span="27 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M712" type="Precipitant" span="103 9" str="phenytoin" code="N0000006023"/>
<Mention id="M714" type="Precipitant" span="63 9" str="rifabutin" code="N0000007464"/>
<Mention id="M716" type="Precipitant" span="52 8" str="rifampin" code="N0000006026"/>
<Mention id="M718" type="Precipitant" span="75 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M720" type="Precipitant" span="131 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I348" type="Pharmacokinetic interaction" trigger="M719" precipitant="M706" effect="C54356"/>
<Interaction id="I349" type="Pharmacokinetic interaction" trigger="M719" precipitant="M708" effect="C54356"/>
<Interaction id="I350" type="Pharmacokinetic interaction" trigger="M719" precipitant="M710" effect="C54356"/>
<Interaction id="I351" type="Pharmacokinetic interaction" trigger="M719" precipitant="M712" effect="C54356"/>
<Interaction id="I352" type="Pharmacokinetic interaction" trigger="M719" precipitant="M714" effect="C54356"/>
<Interaction id="I353" type="Pharmacokinetic interaction" trigger="M719" precipitant="M716" effect="C54356"/>
<Interaction id="I354" type="Pharmacokinetic interaction" trigger="M719" precipitant="M718" effect="C54356"/>
<Interaction id="I355" type="Pharmacokinetic interaction" trigger="M719" precipitant="M720" effect="C54356"/>
</Sentence>
<Sentence id="203" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>Avoid co-administration of CYP 3A inducers ( e.g. , rifampin , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine , St.   John 's   Wort ) with SAMSCA , as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment .</SentenceText>
<Mention id="M735" type="Trigger" span="190 12;207 20" str="reduction in | plasma concentration"/>
<Mention id="M722" type="Precipitant" span="88 12" str="barbiturates" code="N0000008016"/>
<Mention id="M724" type="Precipitant" span="115 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M726" type="Precipitant" span="27 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M728" type="Precipitant" span="103 9" str="phenytoin" code="N0000006023"/>
<Mention id="M730" type="Precipitant" span="63 9" str="rifabutin" code="N0000007464"/>
<Mention id="M732" type="Precipitant" span="52 8" str="rifampin" code="N0000006026"/>
<Mention id="M734" type="Precipitant" span="75 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M736" type="Precipitant" span="131 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I356" type="Pharmacokinetic interaction" trigger="M735" precipitant="M722" effect="C54356"/>
<Interaction id="I357" type="Pharmacokinetic interaction" trigger="M735" precipitant="M724" effect="C54356"/>
<Interaction id="I358" type="Pharmacokinetic interaction" trigger="M735" precipitant="M726" effect="C54356"/>
<Interaction id="I359" type="Pharmacokinetic interaction" trigger="M735" precipitant="M728" effect="C54356"/>
<Interaction id="I360" type="Pharmacokinetic interaction" trigger="M735" precipitant="M730" effect="C54356"/>
<Interaction id="I361" type="Pharmacokinetic interaction" trigger="M735" precipitant="M732" effect="C54356"/>
<Interaction id="I362" type="Pharmacokinetic interaction" trigger="M735" precipitant="M734" effect="C54356"/>
<Interaction id="I363" type="Pharmacokinetic interaction" trigger="M735" precipitant="M736" effect="C54356"/>
</Sentence>
<Sentence id="203" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>Avoid co-administration of CYP 3A inducers ( e.g. , rifampin , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine , St.   John 's   Wort ) with SAMSCA , as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment .</SentenceText>
<Mention id="M751" type="Trigger" span="190 12;207 20" str="reduction in | plasma concentration"/>
<Mention id="M738" type="Precipitant" span="88 12" str="barbiturates" code="N0000008016"/>
<Mention id="M740" type="Precipitant" span="115 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M742" type="Precipitant" span="27 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M744" type="Precipitant" span="103 9" str="phenytoin" code="N0000006023"/>
<Mention id="M746" type="Precipitant" span="63 9" str="rifabutin" code="N0000007464"/>
<Mention id="M748" type="Precipitant" span="52 8" str="rifampin" code="N0000006026"/>
<Mention id="M750" type="Precipitant" span="75 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M752" type="Precipitant" span="131 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I364" type="Pharmacokinetic interaction" trigger="M751" precipitant="M738" effect="C54356"/>
<Interaction id="I365" type="Pharmacokinetic interaction" trigger="M751" precipitant="M740" effect="C54356"/>
<Interaction id="I366" type="Pharmacokinetic interaction" trigger="M751" precipitant="M742" effect="C54356"/>
<Interaction id="I367" type="Pharmacokinetic interaction" trigger="M751" precipitant="M744" effect="C54356"/>
<Interaction id="I368" type="Pharmacokinetic interaction" trigger="M751" precipitant="M746" effect="C54356"/>
<Interaction id="I369" type="Pharmacokinetic interaction" trigger="M751" precipitant="M748" effect="C54356"/>
<Interaction id="I370" type="Pharmacokinetic interaction" trigger="M751" precipitant="M750" effect="C54356"/>
<Interaction id="I371" type="Pharmacokinetic interaction" trigger="M751" precipitant="M752" effect="C54356"/>
</Sentence>
<Sentence id="203" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>Avoid co-administration of CYP 3A inducers ( e.g. , rifampin , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine , St.   John 's   Wort ) with SAMSCA , as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment .</SentenceText>
<Mention id="M767" type="Trigger" span="190 12;207 20" str="reduction in | plasma concentration"/>
<Mention id="M754" type="Precipitant" span="88 12" str="barbiturates" code="N0000008016"/>
<Mention id="M756" type="Precipitant" span="115 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M758" type="Precipitant" span="27 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M760" type="Precipitant" span="103 9" str="phenytoin" code="N0000006023"/>
<Mention id="M762" type="Precipitant" span="63 9" str="rifabutin" code="N0000007464"/>
<Mention id="M764" type="Precipitant" span="52 8" str="rifampin" code="N0000006026"/>
<Mention id="M766" type="Precipitant" span="75 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M768" type="Precipitant" span="131 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I372" type="Pharmacokinetic interaction" trigger="M767" precipitant="M754" effect="C54356"/>
<Interaction id="I373" type="Pharmacokinetic interaction" trigger="M767" precipitant="M756" effect="C54356"/>
<Interaction id="I374" type="Pharmacokinetic interaction" trigger="M767" precipitant="M758" effect="C54356"/>
<Interaction id="I375" type="Pharmacokinetic interaction" trigger="M767" precipitant="M760" effect="C54356"/>
<Interaction id="I376" type="Pharmacokinetic interaction" trigger="M767" precipitant="M762" effect="C54356"/>
<Interaction id="I377" type="Pharmacokinetic interaction" trigger="M767" precipitant="M764" effect="C54356"/>
<Interaction id="I378" type="Pharmacokinetic interaction" trigger="M767" precipitant="M766" effect="C54356"/>
<Interaction id="I379" type="Pharmacokinetic interaction" trigger="M767" precipitant="M768" effect="C54356"/>
</Sentence>
<Sentence id="203" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>Avoid co-administration of CYP 3A inducers ( e.g. , rifampin , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine , St.   John 's   Wort ) with SAMSCA , as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment .</SentenceText>
<Mention id="M783" type="Trigger" span="190 12;207 20" str="reduction in | plasma concentration"/>
<Mention id="M770" type="Precipitant" span="88 12" str="barbiturates" code="N0000008016"/>
<Mention id="M772" type="Precipitant" span="115 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M774" type="Precipitant" span="27 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M776" type="Precipitant" span="103 9" str="phenytoin" code="N0000006023"/>
<Mention id="M778" type="Precipitant" span="63 9" str="rifabutin" code="N0000007464"/>
<Mention id="M780" type="Precipitant" span="52 8" str="rifampin" code="N0000006026"/>
<Mention id="M782" type="Precipitant" span="75 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M784" type="Precipitant" span="131 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I380" type="Pharmacokinetic interaction" trigger="M783" precipitant="M770" effect="C54356"/>
<Interaction id="I381" type="Pharmacokinetic interaction" trigger="M783" precipitant="M772" effect="C54356"/>
<Interaction id="I382" type="Pharmacokinetic interaction" trigger="M783" precipitant="M774" effect="C54356"/>
<Interaction id="I383" type="Pharmacokinetic interaction" trigger="M783" precipitant="M776" effect="C54356"/>
<Interaction id="I384" type="Pharmacokinetic interaction" trigger="M783" precipitant="M778" effect="C54356"/>
<Interaction id="I385" type="Pharmacokinetic interaction" trigger="M783" precipitant="M780" effect="C54356"/>
<Interaction id="I386" type="Pharmacokinetic interaction" trigger="M783" precipitant="M782" effect="C54356"/>
<Interaction id="I387" type="Pharmacokinetic interaction" trigger="M783" precipitant="M784" effect="C54356"/>
</Sentence>
<Sentence id="203" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>Avoid co-administration of CYP 3A inducers ( e.g. , rifampin , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine , St.   John 's   Wort ) with SAMSCA , as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment .</SentenceText>
<Mention id="M799" type="Trigger" span="190 12;207 20" str="reduction in | plasma concentration"/>
<Mention id="M786" type="Precipitant" span="88 12" str="barbiturates" code="N0000008016"/>
<Mention id="M788" type="Precipitant" span="115 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M790" type="Precipitant" span="27 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M792" type="Precipitant" span="103 9" str="phenytoin" code="N0000006023"/>
<Mention id="M794" type="Precipitant" span="63 9" str="rifabutin" code="N0000007464"/>
<Mention id="M796" type="Precipitant" span="52 8" str="rifampin" code="N0000006026"/>
<Mention id="M798" type="Precipitant" span="75 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M800" type="Precipitant" span="131 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I388" type="Pharmacokinetic interaction" trigger="M799" precipitant="M786" effect="C54356"/>
<Interaction id="I389" type="Pharmacokinetic interaction" trigger="M799" precipitant="M788" effect="C54356"/>
<Interaction id="I390" type="Pharmacokinetic interaction" trigger="M799" precipitant="M790" effect="C54356"/>
<Interaction id="I391" type="Pharmacokinetic interaction" trigger="M799" precipitant="M792" effect="C54356"/>
<Interaction id="I392" type="Pharmacokinetic interaction" trigger="M799" precipitant="M794" effect="C54356"/>
<Interaction id="I393" type="Pharmacokinetic interaction" trigger="M799" precipitant="M796" effect="C54356"/>
<Interaction id="I394" type="Pharmacokinetic interaction" trigger="M799" precipitant="M798" effect="C54356"/>
<Interaction id="I395" type="Pharmacokinetic interaction" trigger="M799" precipitant="M800" effect="C54356"/>
</Sentence>
<Sentence id="203" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>Avoid co-administration of CYP 3A inducers ( e.g. , rifampin , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine , St.   John 's   Wort ) with SAMSCA , as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment .</SentenceText>
<Mention id="M815" type="Trigger" span="190 12;207 20" str="reduction in | plasma concentration"/>
<Mention id="M802" type="Precipitant" span="88 12" str="barbiturates" code="N0000008016"/>
<Mention id="M804" type="Precipitant" span="115 13" str="carbamazepine" code="N0000007470"/>
<Mention id="M806" type="Precipitant" span="27 15" str="CYP 3A inducers" code="n0000190118"/>
<Mention id="M808" type="Precipitant" span="103 9" str="phenytoin" code="N0000006023"/>
<Mention id="M810" type="Precipitant" span="63 9" str="rifabutin" code="N0000007464"/>
<Mention id="M812" type="Precipitant" span="52 8" str="rifampin" code="N0000006026"/>
<Mention id="M814" type="Precipitant" span="75 10" str="rifapentin" code="xjm390a33u"/>
<Mention id="M816" type="Precipitant" span="131 20" str="St.   John 's   Wort" code="N0000022261"/>
<Interaction id="I396" type="Pharmacokinetic interaction" trigger="M815" precipitant="M802" effect="C54356"/>
<Interaction id="I397" type="Pharmacokinetic interaction" trigger="M815" precipitant="M804" effect="C54356"/>
<Interaction id="I398" type="Pharmacokinetic interaction" trigger="M815" precipitant="M806" effect="C54356"/>
<Interaction id="I399" type="Pharmacokinetic interaction" trigger="M815" precipitant="M808" effect="C54356"/>
<Interaction id="I400" type="Pharmacokinetic interaction" trigger="M815" precipitant="M810" effect="C54356"/>
<Interaction id="I401" type="Pharmacokinetic interaction" trigger="M815" precipitant="M812" effect="C54356"/>
<Interaction id="I402" type="Pharmacokinetic interaction" trigger="M815" precipitant="M814" effect="C54356"/>
<Interaction id="I403" type="Pharmacokinetic interaction" trigger="M815" precipitant="M816" effect="C54356"/>
</Sentence>
<Sentence id="204" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>In patients receiving SAMSCA who develop medically significant signs or symptoms of hypovolemia , interrupt or discontinue SAMSCA therapy and provide supportive care with careful management of vital signs , fluid balance and electrolytes .</SentenceText>
</Sentence>
<Sentence id="205" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>The dose of SAMSCA may have to be reduced when SAMSCA is co-administered with P-gp inhibitors , e.g. , cyclosporine see Dosage and Administration ( 2.3 ) , Drug Interactions ( 7.1 ) .</SentenceText>
<Mention id="M819" type="Trigger" span="19 22" str="may have to be reduced"/>
<Mention id="M818" type="Precipitant" span="103 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M820" type="Precipitant" span="78 15" str="P-gp inhibitors" code="n0000185503"/>
<Interaction id="I404" type="Unspecified interaction" trigger="M819" precipitant="M818"/>
<Interaction id="I405" type="Unspecified interaction" trigger="M819" precipitant="M820"/>
</Sentence>
<Sentence id="205" LabelDrug="SAMSCA" section="43685-7">
<SentenceText>The dose of SAMSCA may have to be reduced when SAMSCA is co-administered with P-gp inhibitors , e.g. , cyclosporine see Dosage and Administration ( 2.3 ) , Drug Interactions ( 7.1 ) .</SentenceText>
<Mention id="M823" type="Trigger" span="19 22" str="may have to be reduced"/>
<Mention id="M822" type="Precipitant" span="103 12" str="cyclosporine" code="N0000007346"/>
<Mention id="M824" type="Precipitant" span="78 15" str="P-gp inhibitors" code="n0000185503"/>
<Interaction id="I406" type="Unspecified interaction" trigger="M823" precipitant="M822"/>
<Interaction id="I407" type="Unspecified interaction" trigger="M823" precipitant="M824"/>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Unspecified interaction" precipitant="cyclosporine" precipitantCode="N0000007346"/>
<LabelInteraction type="Unspecified interaction" precipitant="inhibitors of p-gp" precipitantCode="n0000185503"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="potent cyp 3a inducers" precipitantCode="n0000190118" effect="C54356"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="rifampin" precipitantCode="N0000006026" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="rifampin" precipitantCode="N0000006026"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="ketoconazole" precipitantCode="N0000007319" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="moderate cyp 3a inhibitors" precipitantCode="n0000191001" effect="C54355"/>
<LabelInteraction type="Unspecified interaction" precipitant="moderate cyp 3a inhibitors" precipitantCode="n0000191001"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="angiotensin converting enzyme inhibitors" precipitantCode="N0000029130" effect="14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="angiotensin receptor blockers" precipitantCode="N0000000070" effect="14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="potassium sparing diuretics" precipitantCode="N0000175418" effect="14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="desmopressin" precipitantCode="N0000147801" effect="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="lovastatin" precipitantCode="N0000007106" effect="C54357"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="clarithromycin" precipitantCode="N0000007316" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp 3a inhibitors" precipitantCode="n0000191001" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="itraconazole" precipitantCode="N0000006753" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="nefazodone" precipitantCode="N0000007250" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="nelfinavir" precipitantCode="N0000006047" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="ritonavir" precipitantCode="N0000007423" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="saquinavir" precipitantCode="N0000007376" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="telithromycin" precipitantCode="N0000010551" effect="C54355"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="digoxin" precipitantCode="N0000005903" effect="C54610"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="digoxin" precipitantCode="N0000005903" effect="C54613"/>
<LabelInteraction type="Unspecified interaction" precipitant="moderate cyp3a inhibitors" precipitantCode="n0000191001"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="barbiturates" precipitantCode="N0000008016" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="barbiturates" precipitantCode="N0000008016"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="carbamazepine" precipitantCode="N0000007470" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="carbamazepine" precipitantCode="N0000007470"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="cyp 3a inducers" precipitantCode="n0000190118" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="cyp 3a inducers" precipitantCode="n0000190118"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="phenytoin" precipitantCode="N0000006023" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="phenytoin" precipitantCode="N0000006023"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="rifabutin" precipitantCode="N0000007464" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="rifabutin" precipitantCode="N0000007464"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="rifapentin" precipitantCode="xjm390a33u" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="rifapentin" precipitantCode="xjm390a33u"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="st. john's wort" precipitantCode="N0000022261" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="strong inhibitors of cyp 3a" precipitantCode="n0000191001"/>
<LabelInteraction type="Unspecified interaction" precipitant="v2-agonist" precipitantCode="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="p-gp inhibitors" precipitantCode="n0000185503"/>
<LabelInteraction type="Unspecified interaction" precipitant="inducers" precipitantCode="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="st.   john 's   wort" precipitantCode="N0000022261" effect="C54356"/>
<LabelInteraction type="Unspecified interaction" precipitant="st.   john 's   wort" precipitantCode="N0000022261"/>
<LabelInteraction type="Unspecified interaction" precipitant="strong cyp 3a inhibitors" precipitantCode="n00001910011"/>

</LabelInteractions></Label>